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The National Health and Medical Research Council Clinical 
Trials Centre conducts its own clinical trials, provides 
expertise and infrastructure for trials run by other groups, 
and undertakes research aiming to improve both the 
conduct of trials and the resulting clinical evidence.
Since 1988, when the CTC was set up as a research 
centre at the University of Sydney, over 60 000 patients 
have been randomised into its trials. Currently, around 
40 active trials — in cancer, cardiovascular disease and 
neonatology — are being conducted in collaboration 
with networks of clinical investigators across Australia 
and elsewhere. The CTC has played a leading role in 
establishing some of these investigator groups, most 
recently the Cooperative Trials Group for Neuro-Oncology 
and the Australasian Lung Cancer Trials Group.
Trial investigators also participate in international 
collaborations to carry out prospective meta-analysis 
of data from concurrent clinical trials. For example, 
the NeOProM collaboration has been formed by ﬁ ve 
cooperating trial groups, involving over 5000 patients, 
with leadership from the CTC. Developments such as 
this increase the eﬃ  ciency of research and the validity 
of its ﬁ ndings, resulting in beneﬁ t to patients throughout 
the world.
The CTC also has strong links and partnerships with 
government and nongovernment organisations and 
industry. Projects include capacity building for Australian 
health and research, reviews of evidence to assist 
government policy making, and methodological research.
The CTC’s past research has served the Australian 
population well, particularly through reduced cardio-
vascular disease and deaths from heart disease and 
improved survival and better quality of life for patients 
with many types of cancer.
This report covers the CTC’s achievements for the 
biennium, 2006–2007.
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FROM THE DIRECTORS
F R O M  T H E  D I R EC T O R S
In 2006 and 2007, many research projects came to 
fruition in the publication or presentation of ﬁ ndings 
that will have direct application in improving the health 
of people in Australia and internationally. The CTC has 
become an important stakeholder in large-scale clinical 
trials research of genuine international signiﬁ cance to 
public health, with a major impact on practice worldwide.
Notable developments in the biennium were the 
strengthening and development of collaborative activities. 
An example is the initiative to help Australian clinician 
groups to initiate and conduct the next generation of 
trials in oncology. The CTC’s staﬀ , expertise, dedicated 
infrastructure, quality assurance, and new systems have 
allowed high-quality new trials answering important 
clinical questions to come into operation. With funding 
from the NHMRC, the CTC has developed new programs 
to assist Australian investigators wanting to undertake 
new trials. The ‘outreach’ program supports clinical 
investigators via our expertise and data management 
systems. We also oﬀ er infrastructure for cancer trials. 
A partnership with the Cancer Institute NSW aims to 
encourage investigator-initiated oncology trials through 
operational and statistical leadership.
The CTC has long been an advocate of prospective 
registration of clinical trials. The Australian New Zealand 
Clinical Trials Registry, established at the CTC in 2005, is 
concentrating on reﬁ ning its data and accessibility, and is, 
linking into a worldwide system of registers. The number 
of trials registered increases steadily.
Major ongoing trials initiatives include: evaluating 
drugs, radiation, surgery and supportive therapies in early 
and advanced cancer; evaluating international diﬀ erences 
in risk, care and outcomes of patients with acute 
myocardial infarction; and genetic and biomarker studies. 
In oncology, recent achievements have included the 
early results of the Sentinel Node Biopsy versus Axillary 
Clearance (SNAC) trial, completion of the Zoloft’s Eﬀ ects 
on Symptoms and Survival Time in Advanced Cancer 
(ZEST), and publication of the results of the CO.17 trial 
in advanced colorectal cancer. A CTC study has helped 
to resolve the question of whether radiotherapy after 
mastectomy improves survival of patients with breast 
cancer. The analysis examined the diﬀ erences in treatment 
in individual studies and took into account the variation in 
radiation dosage and target volumes, to ﬁ nd that 
radiotherapy does, indeed, lead to better survival at 
5 and 10 years. 
Further results with wide clinical application have 
been emerging from the large international diabetes trial, 
FIELD. The important ﬁ nding that diabetes treatment with 
fenoﬁ brate reduces the need for laser treatment for 
diabetic retinopathy was published in 2007. The earlier 
large cardiovascular trial, LIPID, continues in follow-up. 
Our results showing that the study treatment, pravastatin, 
continues to be safe and beneﬁ cial after many years are 
valuable for patients on long-term cholesterol-lowering 
therapy. The data from both these large trials continue to 
accumulate and to generate new research questions, an 
advantage of the CTC’s multidisciplinary and collaborative 
approach to trial conduct. A current focus is the use of 
biomarkers to investigate patients’ individual risk factors 
and susceptibility to treatment.
The PCAT Collaboration, a research group coordinated 
by researchers in the Netherlands, the United States and 
at the CTC, has undertaken several studies involving 
reanalysis of data to answer questions about treatments 
for patients with acute myocardial infarction. The group 
recently published an article analysing the eﬀ ect of 
treatment delay, with implications for the care of these 
patients. Also, the Cholesterol Treatment Trialists’ 
Collaboration, which is prospectively combining vast data 
from major international cardiovascular trials, presented 
new evidence on the beneﬁ cial eﬀ ects of cholesterol 
lowering for people with diabetes. 
Several new international collaborative groups for 
prospective meta-analysis of data from neonatal trials, 
which include the CTC’s own trials, have been created, 
strengthening our expertise and extending our interest 
in this area. 
An important ongoing activity of the CTC is systematic 
reviews of trials on clinical questions and reviews of new 
technologies. In addition to the ongoing reviews of new 
procedures for the Department of Health and Ageing, we 
have recently completed a series of reviews to inform the 
management of serious rare disorders at nationally 
funded centres. A recent review of published studies 
examined how to discuss dying with patients who have 
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JOHN SIMES
Director
Professor John Simes 
is the foundation 
director of the CTC and 
continues to direct all 
the CTC’s activities. He is 
recognised internationally 
for his expertise in the 
ﬁ elds of clinical trials 
and biostatistics and 
represents the CTC on 
many national and 
international committees. He has fostered clinical trials and 
clinical trial networks in cancer, cardiovascular medicine, 
thrombosis, neonatal medicine and surgery. He has played 
a leading role in many international trials that have led 
to major advances in health care and has for many years 
championed the need for evidence-based clinical research. 
Professor Simes is also a specialist medical oncologist at 
Royal Prince Alfred Hospital.  
ANTHONY KEECH
Deputy director
Professor Keech, 
cardiologist and 
epidemiologist, co-
directs the CTC research 
program. He a leading 
international ﬁ gure in 
lipid and cardiovascular 
clinical trials and is 
chairman of the FIELD 
study on heart disease and 
diabetes. As a professor 
in the Department of Medicine at the University of Sydney, 
he initiates, coordinates, develops and teaches courses for 
medical and other postgraduate students. He also leads 
educational initiatives of the CTC, particularly in the Asia-
Paciﬁ c region. In 2007, he was co-chair of the International 
Clinical Trials Symposium. 
Professor Keech is also a practising consultant cardiologist 
at Royal Prince Alfred Hospital.
advanced life-limiting illnesses, and led to Australian 
guidelines on doctor–patient communication in this area. 
Underpinning all our clinical trials research are novel 
approaches to methods. The CTC’s biostatistics team is 
central to advances in trials methodology. Our research 
team has developed prognostic models for individualised 
decision-making, novel methods for evaluating and 
integrating quality-of-life information, and more eﬃ  cient 
and valid methods for trials research. We have instituted 
new strategies for minimising bias in systematic reviews 
and pioneered the use of prospective meta-analysis as the 
gold standard in combining trial results. Our work includes 
expository papers on trial design, outcome assessment, 
and new insights into the interpretation of trial evidence.
Following on the success of symposiums in 1999 and 
2002, the CTC again hosted the International Clinical 
Trials Symposium, in Sydney in September 2007. Those 
attending were informed and also entertained by 
international keynote speakers and Australian trials 
leaders in a varied program, which included topics in the 
broad themes of partnerships in clinical trials, biological 
and genetic targeted therapies, special groups in clinical 
trials, trials in developing countries, and others. The three-
day scientiﬁ c program was supplemented by a day of 
didactic workshops.
The symposium was also the venue for launching the 
CTC’s new book, Interpreting and Reporting Clinical Trials. 
CTC staﬀ  and their colleagues who wrote the book’s 
chapters have elucidated the international CONSORT 
guidelines in a natural, readable way for clinicians and 
others learning about clinical trials.
As the CTC approaches its 20th anniversary, we can 
look back on having coordinated around 45 multicentre 
randomised trials involving many thousands of patients, 
achieved through establishing and supporting 
collaborative groups and playing a lead role in clinical trial 
initiatives. Their success has been due to the teamwork 
and eﬀ orts of the CTC staﬀ  and those in Australia and 
around the world who work with them. These activities 
have been generously supported by government, non-
government and charitable bodies, industry and other 
sponsors.
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CTC EXECUTIVE: Left to right: Anthony Keech (deputy director), Wendy Hague (clinical trials program director), Kim Russell-Cooper 
(general manager, in attendance) and John Simes (director).
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NEW PROGRAMS TO SUPPORT CLINICAL 
TRIALS RESEARCH IN AUSTRALIA
Collaboration with Australian trials researchers
The CTC provides capacity for clinical trials is through support for Australian researchers 
setting up trials in areas of need. This activity is supported by an NHMRC Enabling grant, 
and:
• aims to ensure the highest quality of clinical trials research in new or high-priority health 
research areas, at all institutions throughout Australia.
• provides resources in clinical trials expertise and web-based clinical trials management 
systems to enable investigator-initiated clinical trials of public good.
• supports new trials, including trials in surgery, trials of current clinical practice, new health 
technologies, clinical management studies, and trials in palliative and supportive care 
and complementary medicine.
This grant has provided for the development of clinical trial procedures, web-based trials 
systems and cooperative group networks as platforms for multicentre trials to be initiated 
and undertaken in NSW and elsewhere.
The management committee for this venture comprises John Simes (chair), Wendy Hague, 
Val Gebski, Jenny Chow, Jonathon Craig from Westmead Hospital, Sydney (independent 
adviser), and Marissa Lassere from St George Hospital, Sydney (independent adviser). Its 
activities are overseen by the CTC’s Scientiﬁ c Advisory Committee.
Infrastructure funding for cancer research
SUPPORT FOR THE CENTRAL FUNCTIONS OF CANCER 
COLLABORATIVE GROUPS
The Australasian Gastro-Intestinal Trials Group (AGITG) and the Australia New Zealand 
Gynaecological Oncology Group (ANZGOG) are established research collaborations, 
coordinated at the CTC. They receive funding from various sources to undertake speciﬁ c 
clinical trials to improve the treatment of people with cancer. 
Their operations have been supported since 2005 by a continuing infrastructure grant from 
the Cancer Institute New South Wales, which has allowed them to strengthen their networks, 
expand their programs and improve the conduct of their trials.
NEW PROGRAMS 
Collaboration with Australian trials 
researchers
Infrastructure funding for cancer 
research
COLLABORATIONS
Research collaborations
Biostatistics Collaboration of Australia
B U I L D I N G  C A PACI T Y  F O R
C L I N I C A L  T R I A L S  R E S E A R C H
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BUILDING CAPACITY FOR CLINICAL TRIALS RESEARCH
Major achievements to date have been:
• increasing the number of sites participating in ANZGOG and AGITG trials in NSW, 
nationally and internationally
• promoting the development of new concepts and trials
• attracting funding from other sources to support individual trials and other infrastructure
• developing and implementing a quality assurance and audit program (p. 20).
PARTNERSHIP TO SUPPORT CANCER TRIAL OPERATIONS, 
BIOSTATISTICS AND AUDIT
Infrastructure for clinical trials is a key requirement for developing good quality clinical 
research. 
The Cancer Institute NSW and the CTC have formed a partnership to provide investigators 
and collaborative groups in New South Wales with access to statistical and operational 
expertise, by means of a continuing grant. 
Major achievements to date attributed in total or in part to this funding include: 
• establishing cancer collaborative groups, including the research program of the 
Australasian Lung Trials Group (ALTG) (p. 22), setting up the Cooperative Trials Group for 
Neuro-Oncology (COGNO) (p. 22), and developing new trials through existing groups 
(for example, with the Australia and New Zealand Melanoma Trials Group (ANZMTG)
• supporting investigators in the design of new clinical trials
• education and training of new investigators in clinical trial methods and protocol 
development. 
The partnership has supported 24 studies, which have evaluated novel therapies or the 
optimal use of existing treatments. It has contributed to the participation of centres across 
the state in clinical trials, with a resulting increase in the proportion of new cancer patients 
enrolling in trials — from less than 2% in 2003 to more than 5%. 
Operational services supported by the partnership include developing study outlines, 
protocols and materials for clinical trials; data systems development; local monitoring; 
internal quality assurance; project management support; and reporting and publications.
ANZGOG–AGITG CLINICAL TRIALS RESEARCH FELLOW
Corona Gainford, clinical trials research fellow and medical oncologist, manages 
the Cancer Institute NSW infrastructure grant which funds her fellowship. At the 
CTC, Corona is a clinical supervisor of cancer trials and participates in developing 
new concepts. She is the co-principal investigator of TRIPOD, a phase II trial of 
intraperitoneal chemotherapy for ovarian cancer (p. 20). 
At the CTC, she teaches clinical trials staﬀ  and also teaches in the University of 
Sydney postgraduate medical program. 
Wendy Hague
Clinical trials program director
Wendy Hague is clinical trials 
program director of the CTC 
and is primarily responsible 
for the successful conduct of 
the CTC’s clinical trials and 
ensuring that trials systems, 
procedures and methods are of 
the highest standard. 
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COLLABORATIONS
The CTC works with organisations around the world in collaborations that lead to better health outcomes in Australia and internationally.
Group Nature of group Activity
Australian New Zealand Breast Cancer 
Trials Group (ANZ BCTG)
Collaborative group for breast cancer trials: Australia, New Zealand
International collaborations: International Breast Cancer Study Group 
(IBCSG), Breast International Group (BIG), International Breast Cancer 
Intervention Study (IBIS)
Statistical centre for group, including 
randomisation
Australian and New Zealand Germ Cell 
Tumour Study Group (ANZGCTG)
Collaborative group for testicular cancer trials: Australia, New Zealand Coordinating centre
ASPIRE Study Group Collaborative group for ASPIRE trial: Australia, New Zealand, United 
Kingdom, India
Coordinating centre
Australasian Gastro-Intestinal Trials Group 
(AGITG)
Collaborative group for gastrointestinal cancer trials: Australia, New 
Zealand
International collaborations: NSABP (USA), ECOG (USA), EORTC 
(Europe)
Coordinating centre
Australasian Germ Cell Trials Group Collaborative group for cancer of testes and ovaries Coordinating centre
Australasian Society of Thrombosis and 
Haemostasis
Professional group undertaking thrombosis trials: Australia, New 
Zealand
Coordinating centre
Australasian Lung Cancer Trials Group (ALTG) Collaborative group for lung cancer trials Coordinating centre
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG)
Collaborative group for gynaecological cancer trials: Australia, New 
Zealand
International collaborations: Gynecological Cancer Intergroup (GCIG), 
International Gynaecological Cancer Intergroup (IGCI), Gynecologic 
Oncology Group (GOG), 
Coordinating centre
Australian New Zealand 
Clinical Trials Registry
National register of Australian clinical trials Coordinating centre
Australian universities University members of Biostatistics Collaboration of Australia Coordinating centre
Cochrane Collaboration Collaborative group undertaking systematic reviews of trial evidence: 
international
Editorial base of the Cochrane Breast 
Cancer Group
       
8 NHMRC CLINICAL TRIALS CENTRE: 2006–2007 RESEARCH REPORT
1
BUILDING CAPACITY FOR CLINICAL TRIALS RESEARCH
Group Nature of group Activity
Cholesterol Treatment Trialists’ 
Collaboration (CTTC)
Collaboration of clinical trial groups studying cholesterol treatments: 
Australia, New Zealand, United Kingdom, United States, Italy
Coordination of meta-analyses in 
heart disease
Cooperative Trials Group for 
Neuro-Oncology
Collaborative group for lung cancer trials Coordinating centre
Department of Health and Ageing Government: Australia Provide assessments of new 
technologies and other research 
services
BCA: biostatistics education
European Organisation for Research 
and Treatment of Cancer
International collaborative group Collaborator through Australian 
groups
FIELD Study Group Collaborative group for FIELD diabetes trial: Australia, New Zealand, 
Finland
Coordinating centre
Flinders Medical Centre, Australia Clinical and laboratory centre: Australia Co-collaborator on VIGOUR trials
Gynaecologic Cancer Intergroup (GCIG) International collaborative group Collaborator through ANZGOG
Gynecologic Oncology Group (GOG) International collaborative group Collaborator through ANZGOG
Inhaled nitric oxide for preterm infants Meta-analysis collaboration: Australia, United States, Canada Collaborator
INIS Study Group Collaborative group for INIS trial: Australia, New Zealand, 
United Kingdom
Regional coordinating centre
INSPIRE Meta-analysis: ASPIRE and WARFASA (Italy) Member
LIPID Study Group Collaborative group for LIPID cholesterol-lowering trial: Australia, 
New Zealand
Coordinating centre
Medical Research Council (MRC) Government, international Collaborator
National Cancer Institute of Canada 
Clinical Trials Group (NCIC CTG)
Trials research group: Canada Collaboration on cancer trials and 
meta-analysis
National Heart Foundation Nongovernment organisation: Australia Sponsor of the LIPID trial
National Perinatal Epidemiology Unit 
(NPEU), University of Oxford
Research institution: UK Co-collaborator on the INIS neonatal 
trial
National Surgical Adjuvant 
Breast and Bowel Project (NSABP)
Collaborative group Collaborator through Australian 
groups
NeOProM collaborative group Meta-analysis collaboration Coordinating centre
NSW Cooperative Oncology Group Collaborative group: NSW Coordinating centre for the group
Oxford Clinical Trials Oﬃ  ce (OCTC) Trials research group: UK Cancer trials
PARIS collaborative group Meta-analysis collaboration with representation from many countries Co-coordinating centre
PreVILIG collaborative group Meta-analysis international collaboration Member
Primary Coronary Angioplasty versus 
Thrombolysis (PCAT)
Meta-analysis collaboration with representation from many countries Co-coordinating centre
Prospective Pravastatin Pooling project Collaborative group: Australia, New Zealand, United States, Scotland Coordinating centre
Royal Australasian College of Surgeons Professional society undertaking trials of surgery: Australia and New 
Zealand
Coordinating the SNAC trial in breast 
cancer with the RACS
VIGOUR group Collaborative group for trials of heart disease: 40 countries Data coordinating centre, Asia-Paciﬁ c 
Region; International statistical centre 
(HERO-2 trial)
       
 NHMRC CLINICAL TRIALS CENTRE: 2006–2007 RESEARCH REPORT 9
BU
ILD
IN
G
 CA
PA
CITY FO
R CLIN
ICA
L TRIA
LS RESEA
RCH
PARTICIPATING UNIVERSITIES
Adelaide University (new in 2007)
Australian National University
Macquarie University
Monash University
Newcastle University
University of Melbourne
University of Queensland
University of Sydney
Biostatistics Collaboration of Australia (BCA): 
training a new generation of biostatisticians
The Biostatistics Collaboration of Australia 
(BCA), administered at the CTC, was 
formed in 2001 to meet the need for 
well-trained biostatisticians in Australia. 
No single Australian university has the 
capacity to oﬀ er a comprehensive national 
postgraduate program in biostatistics. 
The BCA program, developed by academic 
statisticians from around the country, is a 
model of collaboration among universities: 
each university recognises the course 
units developed or taught by the other 
universities. Teaching by distance methods, 
initially necessitated by the widely dispersed 
faculty, is now seen to be a strength, 
because of its evidence convenience for 
working students.
The courses provide a sound 
mathematically based grounding in 
statistical methods with a strong emphasis 
on application to all areas of health and medical research. 
The group recently developed an additional core unit, ‘Probability and distribution theory’. 
Statisticians at the CTC contribute to the program by developing, coordinating and 
teaching various units of study, including ‘Principles of statistical inference’ (Adrienne Kirby, 
coordinator) and ‘Advanced clinical trials and meta-analysis’ (Peta Forder and Val Gebski, 
coordinators). 
The BCA program has been re-funded by the Australian Government for a further ﬁ ve years, 
to 2010, providing partial support for the transaction costs incurred by the multi-university 
consortium model.
www.bca.edu.au
Sarah Goodman-Jones, administrative oﬃ  cer, and Erica Jobling, executive oﬃ  cer, 
at the BCA coordinating centre.
In 2007, 224 students were 
enrolled. By the end of 2007,  
over 100 had graduated.
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RESEARCH HIGHLIGHTS
FIELD eye study
IMPORTANT CLINICAL IMPLICATIONS FROM NEW RESULTS 
OF THE FIELD TRIAL
The leading cause of vision loss among working adults in most countries is diabetic 
retinopathy (in which blood vessels of the retina become damaged, causing growth of 
new vessels, bleeding, or swelling at the back of the eye). While laser therapy is a successful 
treatment in preventing blindness, it sometimes causes ocular side-eﬀ ects and reduces the 
visual ﬁ eld. 
One of the studies in the Fenoﬁ brate Intervention and Event Lowering in Diabetes (FIELD) 
trial investigated whether the use of fenoﬁ brate could reduce the rate of laser therapy in 
people with type 2 diabetes (p. 26). This multinational trial had 9795 patients aged 50 to 75 
years from Australia, New Zealand and Finland. 
Laser therapy was more commonly needed in patients with poorer blood glucose and blood 
pressure control and in those with other complications of diabetes. Fenoﬁ brate reduced 
laser treatments for proliferative retinopathy by 30% and for macular oedema by 31%. These 
beneﬁ ts of fenoﬁ brate were apparent after only eight months into the ﬁ ve-year study.
The mechanism of the eﬀ ect was not related to the concentrations of lipids in the blood, and 
may reﬂ ect anti-inﬂ ammatory or antioxidant eﬀ ects of the drug. This ﬁ nding is likely to have 
major clinical implications for the prevention of retinopathy and has led to great interest in 
the scientiﬁ c community.
The study (with the retinopathy substudy) was published in The Lancet in 2007.
RETINOPATHY SUBSTUDY
In a substudy of 1012 FIELD patients, 
serial photography was used to track 
the progress of retinal disease and 
the eﬀ ects of fenoﬁ brate treatment. 
Photographs were taken at baseline, 
2 years, 5 years and the end of the 
study. 
Patients on fenoﬁ brate were less 
likely to have two steps of progression 
of retinopathy grade, macular 
oedema, or laser treatment. This 
was an exploratory ﬁ nding requiring 
conﬁ rmation with a larger group of 
patients.
2
R E S E A R C H  H I G H L I G H T S
Right: Professor Anthony Keech, chief 
investigator of the international FIELD trial.
Photograph of the retina, showing 
branching retinal blood vessels with 
microaneurysms and small haemorrhages.
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High points in gastrointestinal cancer research
CETUXIMAB IMPROVES SURVIVAL
Results of the CO.17 trial were published in 2007 in the New England Journal of Medicine.
CO.17 was designed to determine how cetuximab aﬀ ects the duration of survival and quality 
of life of very ill people with advanced colorectal cancer whose cancer has progressed after 
chemotherapy. Cetuximab is a monoclonal antibody which targets a protein on the surface 
of many cancer cells and some normal cells, inhibiting cell growth and leading to cell death.
Compared with supportive care alone, weekly treatment with cetuximab resulted in a 
statistically signiﬁ cant 23% improvement in overall survival. There was also a 32% reduction 
in the risk of disease progression. Patients treated with cetuximab also had less deterioration 
in quality-of-life scores. 
The average improvement in survival was a result of the better survival of the minority of 
patients whose tumour responded to treatment. It is not yet known how these particular 
patients can be identiﬁ ed. However, one ﬁ nding of the study was that patients in the 
cetuximab group had a high incidence of rashes, and those with worse rashes survived for 
longer. Rashes or hypersensitivity related to growth-factor inhibition could be investigated 
as a potential biomarker predicting patients most likely to beneﬁ t from treatment. 
The trial was a study by the Australasian Gastro-Intestinal Trials Group in conjunction 
with the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). The CTC 
coordinated the CO.17 trial in Australia, New Zealand and Singapore.
MAX: COMBINATION 
TREATMENT COMPARED 
WITH A SINGLE DRUG FOR 
COLORECTAL CANCER 
The MAX study is determining 
the optimal low-toxicity regimen 
for a broad range of patients 
with advanced colorectal cancer. 
The rationale for the treatment 
is a comparison of the standard 
chemotherapy, capecitabine, with 
capecitabine and a biological agent, 
bevacizumab, with or without 
mitomycin C. The study aims to 
improve the duration of survival 
without compromising quality 
of life. 
Recruitment exceeded expectations 
in 2006. In spite of an amendment 
in August 2006 to increase 
the sample size from 333 to 
450 patients, recruitment was 
completed, with 471 patients, in 
2007.
This trial is signiﬁ cant as the ﬁ rst 
international oncology study led 
and coordinated by the AGITG and 
CTC.  Although some patients will 
still be in follow-up over the coming 
months, early publications are 
emerging for major international 
conferences in 2008.
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RESEARCH HIGHLIGHTS
ZEST: Depression and quality of life in 
advanced cancer
Self-ratings of depression, mood, fatigue, and global quality of life are related to survival in 
advanced cancer.
The recently completed ZEST trial (Zoloft’s Eﬀ ects on Symptoms and Survival Time in 
Advanced Cancer) considered whether treatment with antidepressants might improve 
psychological wellbeing in patients with advanced cancer and consequently prolong their 
survival by helping them to cope better with their illness and treatment.
The trial used an established selective serotonin reuptake inhibitor — sertraline — in 
patients with advanced cancer who felt depressed, anxious, tired, or who had low energy, but 
who were not thought to have major depression.
ZEST began in 2001 with a planned sample size of 440 patients. After about 189 patients 
had been recruited, the ﬁ rst interim analysis showed that survival was shorter with sertraline, 
so recruitment was stopped. With further follow-up, the diﬀ erence between the groups 
became less apparent, and was considered a chance ﬁ nding. 
For patients with advanced cancer who do not have major depression, sertraline did not 
improve wellbeing and did not improve survival.
This study had notable methodological strengths: its double-blind, randomised design 
(blinding was maintained after the interim results for the group were made available to 
clinicians and patients); the use of multiple, validated outcome measures; and enrolment of 
a broad cross-section of patients with advanced cancer; and excellent compliance. The results 
were published in The Lancet in 2007.
Does radiation therapy improve survival 
after breast cancer?
An analysis of survival after breast cancer used published data and modern knowledge of 
treatment to resolve the controversy over whether radiation therapy improves survival. It 
was known that radiation therapy after mastectomy reduces the risk of recurrence of breast 
cancer, but its eﬀ ects on overall survival had been less clear. 
The CTC study ﬁ rst excluded previous trials in which the eﬀ ects of radiotherapy were 
confounded by diﬀ erent types of surgery. Then, in an analysis of data from 36 clinical trials, 
the ingenious approach to answering the research question was to divide the trials into three 
categories: studies that used optimal radiation doses delivered to an appropriate amount of 
tissue; studies in which the dosage of radiation was too high or too low; and studies in which 
the amount of tissue treated was not adequate.
In the trials in which patients received well-targeted treatment, more patients who had had 
radiotherapy survived at 5 years and at 10 years. If the dosage or the area of tissue treated 
was not accurate, radiation did not make a diﬀ erence to survival. The study’s ﬁ ndings were 
considered to be the most plausible or realistic estimates of improved outcome associated 
with modern radiation therapy, which will assist doctors and patients in their decision 
making. 
In their paper in the Journal of the National Cancer Institute, the authors recommended that 
postmastectomy radiation therapy now be considered for all patients at high risk. 
“Treatment with a selective 
serotonin reuptake inhibitor 
should be reserved for those 
with a proven indication.”
— conclusion of the ZEST trial
Val Gebski
Head of Biostatistics and ﬁ rst 
author of the radiotherapy study
2
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First results of the SNAC breast cancer trial
SNAC
The SNAC (Sentinel Node Biopsy versus Axillary Clearance) trial was the ﬁ rst large trial of 
surgical treatment of breast cancer in Australasia. 
The trial aimed to ascertain whether biopsy of a few sentinel lymph nodes would reduce the 
side-eﬀ ects — arm swelling, pain and disability — that often aﬀ ect women who have had the 
standard treatment, full clearance of the lymph nodes. Recruitment was very fast, and 1088 
patients enrolled over four years. 
Results after 12 months of follow-up showed that women allocated to sentinel-lymph-node 
biopsy had fewer problems with arm swelling, movement, sensation and other aspects of 
quality of life than women allocated to routine axillary clearance. However, arm swelling was 
worse at one year than at six months, and longer follow-up is needed to see what happens 
in later years. 
Clinical management based on sentinel-lymph-node biopsy was as accurate for diagnosis as 
axillary clearance, for women with single, small tumours. This underlines the importance of 
women attending for regular screening, so that cancers are detected as early as possible. 
Follow-up in the SNAC trial will continue for at least 10 years. 
SNAC 2
SNAC 2 is an extension of the SNAC trial, and began recruitment early in 2006. 
It is investigating sentinel-node-based management of the axilla for a wider range of 
women, including women with multiple primary tumours in the same breast and women 
with large tumours. The trial will measure the risk of recurrence of the tumour, particularly in 
the axilla. Also, the diagnostic accuracy of sentinel-lymph-node biopsy is a particular focus.
“The RACS SNAC trial was the 
fastest recruiting cancer trial 
ever conducted in Australia.
This excellent result came about 
because of the collaboration of 
the women who participated, 
the investigators conducting the 
trial and their data management 
teams combined with the 
diligence of the staﬀ  
at the NHMRC Clinical
Trials Centre.”
— SNAC chairman, 
Professor Grantley Gill
FUNDING
The Royal Australasian College 
of Surgeons and the CTC have 
collaborated in conducting 
the SNAC trial, which has been 
funded by:
• MBF Australia, the Department 
of Health and Ageing 
• National Health and Medical 
Research Council
• National Breast Cancer 
Foundation
• Scottwood Trust, New Zealand
       
THIRD INTERNATIONAL CLINICAL TRIALS SYMPOSIUM
KEYNOTE SPEAKERS
Professor Doug Altman
Professor of Statistics in Medicine at 
the University of Oxford, and founding 
director of Oxford’s Centre for Statistics 
in Medicine
Professor Robert Caliﬀ 
Vice Chancellor for Clinical Research, 
Director of the Duke Translational 
Medicine Institute, and Professor of 
Medicine in the Division of Cardiology 
at Duke University Medical Center in 
Durham, North Carolina
Professor Paul Glasziou
Director of the Centre for Evidence-Based 
Medicine, Professor of Evidence-Based 
Medicine in the Department of Primary 
Health Care at the University of Oxford, 
and part-time general practitioner
Dr Richard Horton
Editor, Lancet Publishing Group
Dr Joseph Pater
Former director of the National Cancer 
Institute of Canada Clinical Trials Group
Following the success of the international symposiums in Sydney in 1999 and 2002, the CTC 
again hosted the International Clinical Trials Symposium, in September 2007.
Internationally recognised experts in clinical trials research were invited from Australasia, 
America and Europe to speak. Presenters and delegates came from 15 countries, 
representing 185 organisations. A diverse and stimulating program on topical issues was 
delivered via workshops, plenary sessions, invited presentations, free papers, focus groups 
and panel sessions. A popular event was the now-traditional symposium debate, where the 
panellists paraded their erudition and life experience on a knife edge of good taste to oﬀ er a 
new slant on clinical trials.  
Representatives from academia, regulatory bodies, the pharmaceutical industry and health 
care organisations exchanged ideas on the practical aspects of undertaking clinical trials 
research and translating these trials results into improvements in clinical practice.
Some of the themes for the third symposium had arisen from questions raised in the second 
symposium. Others were current topics warranting exploration and discussion. Themes 
were: partnerships among government, industry and academia; frontiers in statistical 
methods, including adaptive designs; biological and genetic therapies; nonpharmacological 
technologies; and translating trials research into practice.
At the symposium, the NSW Oﬃ  ce for Science and Medical Research announced 
seed funding for the development of a national curriculum in training in clinical trials 
management. The ﬁ rst project will be a course for senior clinical researchers to be held by 
the CTC and other Sydney research groups, in conjunction with Harvard University, early in 
2008. 
3
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PRESYMPOSIUM WORKSHOPS
160 people attended the four presymposium workshops organised 
by the CTC and presented by CTC staﬀ  and invited experts.
1: Biomarkers and surrogate evaluation
Topics included real-world experiences in cancer trials, ethical 
issues to do with tissue banks and international collaborations, 
biomarkers as surrogates for clinical endpoints and systematic 
evaluation of surrogacy evidence in cardiovascular disease, HIV 
medicine and oncology.
2: Updates for clinical trial managers
The workshop covered recruitment and retention strategies 
from the perspectives of the coordinating centre and the sites, 
performing well at an audit, interpreting trial results, and resources 
for phase I trials.
3: Publications: getting your research published
The presenters were dominant ﬁ gures in publishing and leading 
researchers, who led discussion on CONSORT guidelines, preparing 
manuscripts and the practice and interpretation of statistics.
4: Health technology assessment: interpreting trial evidence for 
policy decisions
Nonpharmaceutical trials and assessments present challenges. This 
workshop had sessions on conducting trials of surgery and clinical 
devices, decision analysis and Australian regulatory policies.
SPONSORS
Principal sponsor/partner: Department of Health and Ageing 
Partner: National Health and Medical Research Council
Gold sponsor: New South Wales Department of Health
Silver sponsor: Oﬃ  ce for Science and Medical Research
Supporting sponsors: 
•  Association of Regulatory and Clinical Scientists
•  GlaxoSmithKline
•  Roche
International Clinical Trials
Symposium 2007
INTERPRETING AND 
REPORTING CLINICAL TRIALS
The CTC’s popular 
new textbook was 
published in 2007 
and launched at the 
International Clinical 
Trials Symposium. 
Interpreting and 
reporting clinical trials: a 
guide to the CONSORT 
statement and the 
principles of randomised 
controlled trials, edited 
by Tony Keech, Val 
Gebski and Rhana Pike, covers the fundamentals of clinical 
trials. CTC staﬀ  predominate among the chapter authors.
The book has been well received by its target 
readers — clinicians, trial coordinators, students and 
others — meeting their needs for a readable but 
comprehensive compilation of up-to-date knowledge.
It explains and expands on the items of the CONSORT 
statement, the international standard for reporting clinical 
trials. Its contents include randomisation, blinding, sample 
size calculation, basic statistical methods, how to deal with 
subgroups, and the interpretation and generalisability of 
results, supplemented by checklists and case studies.
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IMPROVING QUALITY OF LIFE     AND SURVIVAL IN CANCER 
Kathleen Scott, head of 
site management with 
Burcu Vachan, oncology 
program manager.
GASTROINTESTINAL CANCER
GYNAECOLOGICAL CANCER
AUDIT PROGRAM
GERM CELL TRIALS
LUNG CANCER
NEURO-ONCOLOGY (COGNO)
BREAST CANCER
COLLABORATION AND LEADERSHIP IN 
ONCOLOGY TRIALS
The CTC has long-standing relationships with national cancer cooperative groups and is 
well represented in clinical trials initiatives in cancer. It has collaborated in over 60 cancer 
trials recruiting 10 000 patients in breast, oesophageal, gastric, colorectal and gynaecological 
cancers and melanoma. 
In the province of the conduct of trials, the CTC covers the full range of 
responsibilities — from assisting in establishing new groups by creating a research 
governance structure and terms of reference, identifying important questions related to 
public health — through to large-scale trial operations in collaboration with the groups, for 
example, in concept and protocol development, randomisation, data collection, ethics 
and regulatory compliance, on-site monitoring and audit, and analyses and manuscript 
preparation.
As a member of existing international collaborations, the CTC has recently taken the lead as 
coordinating centre for international trials, for example, the MAX colorectal cancer trial in 
the United Kingdom, and the HOSTT cervix cancer study in Taiwan.
The CTC expects to continue its strong associations with the existing national cancer 
cooperative groups as part of a ﬂ ourishing oncology program.
4
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ONCOLOGY EXECUTIVE 
COMMITTEE
Director of the CTC:  
John Simes
Oncology co-director: 
Martin Stockler
Clinical trial program director: 
Wendy Hague
Oncology program manager: 
Burcu Vachan
Head of biostatistics: 
Val Gebski
Senior biostatistician: 
Patrick FitzGerald
Clinical research fellow: 
Corona Gainford
ONCOLOGY SCHOLAR
Peter Grimison is a medical 
oncologist with a particular 
interest in the conduct of cancer 
clinical trials. He is the chair of 
the Accelerated BEP trial and has 
assisted the trials of the ANZGCTG.  
He is a Cancer Institute NSW 
Scholar and holds an NHMRC 
Postgraduate Research Scholarship 
for PhD study on quality-of-life 
assessment in clinical trials.
ROLES OF THE CTC IN CANCER COLLABORATIVE GROUPS
NATIONAL CANCER COOPERATIVE GROUPS CENTRAL OFFICE, 
INCLUDING TRIAL 
OPERATIONS
STATISTICAL 
OFFICE 
Australasian Gastro-Intestinal Trials Group 
(AGITG) CTC CTC
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG)
CTC CTC
Australian and New Zealand Germ Cell Trials 
Group (ANZGCTG)
CTC CTC
Australasian Lung Cancer Trials Group (ALTG) CTC and 
Peter MacCallum 
Cancer Institute 
CTC and 
Peter MacCallum 
Cancer Institute 
Cooperative Trials Group for Neuro-Oncology 
(COGNO)
CTC CTC
Australia New Zealand Melanoma Trials Group 
(ANZMTG)
Sydney Melanoma 
Unit and CTC
No central 
statistical centre.
Australian New Zealand Breast Cancer Trials 
Group (ANZ BCTG)
University of 
Newcastle 
CTC (statistics and 
randomisation)
INTERNATIONAL CANCER COOPERATIVE GROUPS
National Surgical Adjuvant Breast and Bowel Project (NSABP)
National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)
Gynaecologic Cancer Intergroup (GCIG)
Gynecologic Oncology Group (GOG)
European Organisation for Research and Treatment of Cancer (EORTC)
Oxford Clinical Trials Oﬃ  ce (OCTO)
Medical Research Council (MRC)
Eastern Cooperative Oncology Group (ECOG)
European Study Group for Pancreatic Cancer (ESPAC)
Pan-European Trials in Alimentary Tract Cancer (PETACC)
Trans-Tasman Radiation Oncology Group (TROG)
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The Australasian Gastro-Intestinal Trials Group
The CTC is the coordinating centre for the Australasian Gastro-Intestinal Trials Group 
(AGITG), which has an active network of clinical investigators across Australia and New 
Zealand. The AGITG has 560 members, mainly from Australia and New Zealand, but also 
from Canada, Singapore, United Kingdom, Hong Kong, Germany and the United States. 
Since it began in 1991, the group has conducted 26 trials and recruited more than 2500 
patients to investigator-initiated trials from over 65 sites. While recruitment increased from 
356 in 2005 to 488 in 2006, 2007 saw 225 patients recruited to AGITG trials. 
During 2007, trial activity remained strong, with a greater proportion of trials in active 
follow-up after closure and only one new trial opening. Preliminary work by the CTC is 
underpinning four AGITG-developed trials which will open to recruitment in 2008 and two 
international intergroup studies.
AGITG TRIALS
Trial Participants Interventions Main outcome 
measures
Status
CURRENT TRIALS
Da Vinci: 
Phase II trial of De Gramont schedule 5-ﬂ uorouracil 
and leucovorin plus irinotecan versus single-agent 
irinotecan in patients with previously treated 
metastatic colorectal cancer (AGITG study)
Patients with previously 
treated metastatic 
colorectal cancer
• irinotecan + 
5-ﬂ ourouracil + 
leucovorin
• irinotecan
• toxicity
• safety
• quality of life
• survival
Recruitment target: 100
Recruitment: 88
EORTC 62024: 
Gastrointestinal stromal tumours (GIST) expressing 
KIT receptor: adjuvant imatinib mesylate (Glivec) 
versus no further therapy after surgery
(EORTC study)
Patients with fully 
resected gastrointestinal 
stromal tumour
• imatinib
• no therapy
• survival
• relapse-free survival
• relapse-free interval
Recruitment target: 80
Recruitment: 66
ESPAC-3: 
European study of adjuvant chemotherapies in 
resectable pancreatic cancer (ESPAC study)
Patients with operated 
cancer of the pancreas
• surgery + 5-
ﬂ uorouracil + 
leucovorin
• gemcitabine
• surgery
• survival
• progression-free 
survival
Recruitment target: 150
Recruitment: 133
Quasar 2: 
Phase III study of capecitabine and bevacizumab as 
adjuvant treatment of colorectal cancer 
(OCTO study)
Patients with colon 
cancer treated by 
surgery
• capecitabine
• capecitabine + 
bevacizumab 
• disease-free survival Recruitment target: 120 
Recruitment: 48
TRIALS IN FOLLOW-UP
ABC: 
Phase II trial of gemcitabine in ﬁ xed dose rate 
infusion compared with cisplatin in patients with 
biliary tract carcinoma (AGITG study)
Patients with inoperable 
biliary tract carcinoma
• gemcitabine
• cisplatin
• tumour response
• safety
Closed
Recruitment: 50
ATTAX: 
Phase II study evaluating a weekly schedule of 
docetaxel with cisplatin and 5-ﬂ uorouracil or 
capecitabine (AGITG study)
Patients with advanced 
oesophageal or gastric 
cancer
• docetaxel, cisplatin, 
5-ﬂ uorouracil
• docetaxel, 
capecitabine
• tumour response Closed.
Recruitment: 106
ATTAX 2: 
Phase II study of cetuximab plus docetaxel in 
docetaxel-refractory patients (AGITG study)
Patients with advanced 
oesophageal or gastric 
cancer
• cetuximab + 
docetaxel
• tumour response Closed.
Recruitment: 38
4
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Trial Participants Interventions Main outcome 
measures
Status
CO.17: 
Phase III study of cetuximab and best supportive 
care versus best supportive care in patients with 
pretreated metastatic epidermal-growth-factor-
receptor (EGFR-positive colorectal carcinoma)
(NCIC CTG–AGITG study)
Patients with pretreated 
metastatic colorectal 
cancer with positive 
EGFR
• cetuximab + 
supportive care
• supportive care
• survival
• time to progression
• response
• quality of life
Closed.
Recruitment: 252
Gofurtgo: 
Phase II study of ﬁ xed dose rate gemcitabine–
oxaliplatin with 5-ﬂ uorouracil and radiotherapy to 
treat localised pancreatic cancer
(AGITG study)
Patients with localised 
pancreatic cancer
• radiotherapy, 
gemcitabine and 
oxaliplatin
• tumour response
• safety
Closed.
Recruitment: 48
MAX: 
Phase II–III study to evaluate the role of Mitomycin 
C [mitomycin], Avastin [bevacizumab] and Xeloda 
[capecitabine] in patients with untreated metastatic 
colorectal cancer 
(AGITG study)
Patients with previously 
untreated metastatic 
colorectal cancer
• capecitabine
• capecitabine + 
bevacizumab
• capecitabine + 
bevacizumab + 
mitomycin
• toxicity
• response
• progression-free 
survival
• quality of life
Closed.
Recruitment: 471
C06: 
Oral uracil and ftorafur + leucovorin compared with 
5-ﬂ uorouracil + leucovorin for patients with stages 
II and III carcinoma of the colon
(NSABP study)
Patients with 
stage II or stage IIII 
adenocarcinoma, no 
metastatic disease and 
a life expectancy of at 
least 10 years (excluding 
diagnosis of cancer)
• 5-ﬂ uorouracil + 
leucovorin
• UFT (tegafur and 
uracil) + leucovorin
• disease-free survival
• survival
• quality of life
• prognostic 
signiﬁ cance of 
genetic and biological 
markers
Closed.
Recruitment: 11
C07: 
5-ﬂ uorouracil plus leucovorin compared with 
oxaliplatin with 5-ﬂ uorouracil + for the treatment of 
patients with stages II and III carcinoma of the colon
(NSABP study)
Patients with resected 
stage II or stage III colon 
carcinoma
• 5-ﬂ uorouracil + 
leucovorin
• 5-ﬂ uorouracil + 
oxaliplatin
• disease-free survival
• survival
Closed.
Recruitment: 134
EORTC 62005: 
Phase III study of two diﬀ erent doses of imatinib 
mesylate in patients with CD117-expressing 
metastatic or unresectable gastrointestinal stromal 
tumour
(EORTC study)
Patients with metastatic 
gastrointestinal stromal 
tumour
• imatinib twice daily
• imatinib once daily
• progression-free 
survival
• survival
• tumour response
Closed.
Recruitment: 116
EORTC 40983: 
Phase III preoperative and postoperative 
chemotherapy with oxaliplatin + 5-ﬂ uorouracil + 
leucovorin versus surgery alone in resectable liver 
metastases of colorectal origin
(EORTC Study)
Colon cancer with liver 
metastases
• 5-ﬂ uorouracil 
+ leucovorin + 
oxaliplatin
• surgery
• progression-free 
survival
• survival
Closed.
Recruitment: 35
NOTABLE ACHIEVEMENTS
MAX: The MAX study completed recruitment in June 2007 
(p. 11). 
Quasar 2: Quasar 2 is run internationally by the Oncology 
Clinical Trials Oﬃ  ce (OCTO) at Oxford University, and opened in 
Australia and New Zealand in June 2007. In addition to the 35 
sites in Australia and New Zealand, two sites in Hong Kong will 
join this study.
CO.17: The results were published in the New England Journal of 
Medicine in 2007 (p. 11). 
ABC: The results were presented in 2007. 
ATTAX and ATTAX 2: Results were presented at the American 
Society of Clinical Oncology meeting in 2006. The follow-on 
study, ATTAX2, reached full recruitment in 2007.
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IMPROVING QUALITY OF LIFE    
Australia New Zealand Gynaecological 
Oncology Group
The Australia New Zealand Gynaecological Oncology Group (ANZGOG) was established in 
2002 to improve gynaecological cancer treatment and outcomes through a cooperative 
approach. ANZGOG conducts its own clinical trials and participates in international 
collaborative trials. Australia and New Zealand have more than 30 trial sites. All the group’s 
trials are coordinated from the CTC. 
The ﬁ nal results from ANZGOG 0201, the ﬁ rst locally developed ANZGOG study, were 
published in Gynecological Oncology in 2007. 
TRIPOD, a second ANZGOG phase 2 trial, opened to recruitment in 2007. TRIPOD looks at 
the feasibility of intraperitoneal delivery of chemotherapy for ovarian cancer. The New South 
Wales Cancer Council funds the central coordination costs and site payments. 
Two international collaborative-group trials closed to recruitment in 2007, Calypso in 
September and EORTC Tarceva in December. The CTC is the international statistical centre 
for Calypso, and the analysis of toxicity data from the ﬁ rst 200 patients was presented at the 
European Society of Gynaecological Oncology meeting in October 2007.
Two Gynaecological Cancer Intergroup (GCIG) collaborative group trials will open in 2008. 
Symptom Beneﬁ t was developed by ANZGOG and endorsed by the international group. 
PORTEC-3 (Postoperative Radiation Therapy for Endometrial Carcinoma), also has a patient 
preferences substudy which was developed by ANZGOG.
TRIPOD HAS TWO 
INTERESTING SUBSTUDIES: 
1. investigation of the biodistribution 
of chemotherapy drugs in the 
abdominal cavity
2.  evaluation of patients’ preferences 
for receiving chemo therapy via the 
intraperitoneal route instead of the 
standard intravenous infusion.
Julie Martyn
ANZGOG associate program manager
Keeping up the quality of cancer trials
The AGITG and ANZGOG audit program began in May 2006, made possible by infrastructure 
funding from the Cancer Institute (p. 6). Trials are audited internally at the CTC and externally at the 
clinical sites. This program is on target and progressing well. Site staﬀ  have appreciated a review of 
their trial conduct and compliance with regulatory requirements and almost all audits have had a 
satisfactory outcome.
The goal of the audit program, continuous improvement, is being achieved through:
• identiﬁ cation of site diﬃ  culties and reporting of such to the CTC, alerting trial staﬀ  to gaps in 
knowledge as well as management or process diﬃ  culties at trial sites
• on-site incidental training and recommendations during audit
• inclusion of a site’s preventive actions in the responses to audit ﬁ ndings, with reporting of such
• workshops on preparation for audit at meetings of the trial collaborative groups.
Karen Pinto
AGITG–ANZGOG auditor
4
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ANZGOG TRIALS
Trial Participants Interventions Main outcome 
measures
Status
CURRENT TRIALS
TRIPOD: 
Phase II trial of intraperitoneal chemotherapy 
Women with ovarian 
and related cancers
• paclitaxel + cisplatin 
injected into the 
abdominal cavity
• feasibility
• safety
• quality of life
Recruitment target: 
35–100
Recruitment: 5
ICON 7: 
Randomised, two-arm, multicentre GCIG trial of 
adding bevacizumab to standard chemotherapy in 
patients with epithelial ovarian cancer
Women with epithelial 
ovarian cancer who 
have not received 
systemic anti-tumour 
therapy
• bevacizumab + 
standard carboplatin 
and paclitaxel 
• standard carboplatin 
and paclitaxel
• progression-free 
survival
Recruitment target: 90
Recruitment: 5
SCOTROC 4: 
Multicentre randomised trial of carboplatin ﬂ at 
dosing vs intrapatient dose escalation in ﬁ rst-line 
chemotherapy 
Women with ovarian, 
fallopian tube or 
peritoneal carcinoma 
who are unsuitable 
for platinum–taxane 
therapy
• 6 cycles carboplatin, 
ﬁ xed dose
• 6 cycles carboplatin, 
with changes to 
dose depending on 
neutrophil count
• progression-free 
survival
Recruitment target: 150
Recruitment: 41
HOSTT: 
Phase II study to evaluate maintaining 
haemoglobin levels above 120 g/L vs over 100 g/L 
(ANZGOG 0401)
Women with untreated 
cancer of the cervix 
receiving cisplatin and 
radiation therapy
• red cell transfusion • feasibility of 
treatment
• safety
• quality of life
Recruitment: 6 patients 
of 100 for the pilot 
stage of the trial.
TRIALS IN FOLLOW-UP
Tarceva: 
Phase III study of erlotinib versus observation  
(EORTC 55041)
Women with high-risk 
stage I or stages II–IV 
ovarian cancer which 
has not progressed after 
platinum chemotherapy
• maintenance erlotinib
• standard care 
(observation alone)
• progression-free 
survival
Closed
Recruitment: 42
Calypso: 
Caelyx in platinum-sensitive ovarian cancer 
patients
Women whose disease 
has progressed after 
treatment
• pegylated liposomal 
doxorubicin + 
carboplatin
• paclitaxel + 
carboplatin
• progression-free 
survival
Closed
Recruitment: 71
GOG 182:
Phase III randomised trial of paclitaxel + 
carboplatin versus triplet or sequential doublet 
combinations in patients with epithelial ovarian or 
primary peritoneal carcinoma (GOG 182)
Women with advanced 
(stage III or IV) primary 
ovarian or peritoneal 
cancer
• gemcitabine or 
topotecan with 
carboplatin (doublet 
therapy)
• carboplatin + 
paclitaxel (triplet 
therapy)
• survival
• progression-free 
survival
Closed
Recruitment: 183
Prospective study of risk-reducing salpingo-
oophorectomy and longitudinal CA-125 screening 
among women at increased genetic risk of ovarian 
cancer (GOG 199)
Women aged >30 at risk 
of ovarian cancer
• choice of preventive 
surgery
• screening
• incidence of ovarian 
cancer
• prevalence of clinically 
occult ovarian cancer
• predictive value of 
ROCA algorithm
• quality of life
Closed
Recruitment: 83
Phase II trial of weekly docetaxel for patients with 
relapsed ovarian cancer  (ANZGOG 0201)
Women whose disease 
progressed after 
treatment
• docetaxel • toxicity
• time to progression
• survival
Closed
Recruitment: 37
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PATIENT PREFERENCES 
STUDIES
Patient preferences studies are an 
important way of identifying the 
degree of beneﬁ t patients expect to 
accept therapy for their cancer (p. 41). 
These studies have not been done 
for lung cancer patients. The ALTG 
and the CTC are starting to examine 
these issues.
Cooperative Trials Group for Neuro-Oncology 
(COGNO)
The newly formed Cooperative Trials Group for Neuro-Oncology (COGNO) is coordinated 
from the CTC. COGNO plans to take part in and initiate trials to evaluate new therapies and 
interventions to prevent and mitigate disease. Michelle Cummins is the oncology associate 
program manager for COGNO trials, with support from Kathleen Scott.
OBJECTIVES OF COGNO
• To encourage members of the medical and scientiﬁ c community, through participation, 
to assist in the conduct, evaluation, promotion and development of clinical trials in brain 
tumours
• To promote the use of clinical trials evaluating current therapies and new treatments for 
brain tumours and to improve the impact of new clinical trials on future clinical practice
• To promote the incorporation of translational studies into new clinical trials in brain 
tumours.
• To freely publish the results of research and clinical trials and to make available for 
general use, on the same terms to all interested bodies, licences for Australian and 
New Zealand patents issued in the course of research and clinical trials
4
Xanthi Coskinas
Oncology associate program manager
Australasian Lung Cancer Trials Group 
The Australasian Lung Cancer Trials Group (ALTG) was formed in 2004 to support 
investigator-initiated lung cancer trials. The ALTG comprises about 100 members from 
various backgrounds and is working with the CTC as its central coordinating centre.
The CTC and representatives of committees of the ALTG form an operational executive, 
which is responsible for leading the group in developing and managing new trial concepts, 
sought from the ALTG membership and industry. The operational executive then assists 
clinical investigators to develop these ideas from concepts to working protocols. The 
collaboration has ﬁ ve studies in various stages of development.
International collaborations have been established with the National Cancer Institute 
of Canada Clinical Trials Group and the Dutch Association of Physicians for Pulmonary 
Diseases and Tuberculosis group.
TRIALS
MATES: Thalidomide treatment may improve survival and quality of life in people with 
mesothelioma that has stabilised or improved after permetrexed chemotherapy. The 
Maintenance Thalidomide in Mesothelioma Quality of Life and Prognostic Marker Study 
(MATES), a Dutch trial, is investigating thalidomide as a maintenance treatment. The 
recruitment target in Australia is 100 patients of the total of 216 worldwide. The Australian 
group has added two substudies examining quality of life and predictive biomarkers. 
NITRO: Protocol development activities, including feasibility assessment, have started for 
an ALTG trial examining whether adding nitroglycerin patches to chemotherapy will improve 
survival and quality of life. This trial, Nitroglycerin Patches for Non-Small-Cell Lung Cancer 
(NITRO), will be the ALTG’s ﬁ rst home-grown trial. 
IMPROVING QUALITY OF LIFE  AND SURVIVAL IN CANCER 
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The Australian New Zealand Breast Cancer 
Trials Group
The CTC is randomisation and statistical centre for the Australian New Zealand Breast 
Cancer Trials Group (ANZ BCTG). 
The group’s breast cancer trials are coordinated at the operations oﬃ  ce at the University of 
Newcastle. The CTC registers and randomises the trials and also undertakes statistical and 
other analyses of trial data. 
Australian and New Zealand Germ Cell 
Trials Group
The Australian and New Zealand Germ Cell Trials Group (ANZGCTG), an established network 
of over 100 clinicians and researchers, is the only national organisation dedicated to high-
quality clinical research for people aﬀ ected by germ cell cancers. The coordinating centre 
for the group is at the CTC.  
In 2006, the group secured funds for infrastructure from the federal government’s 
Strengthening Cancer Care Initiative, which is now managed by Cancer Australia. This 
funding has been instrumental in the group’s recent expansion, including a concept 
development meeting in July 2006. Promising new research proposals were discussed, 
including a phase II study of a seven-day aprepitant schedule to prevent nausea and 
vomiting in patients receiving chemotherapy for metastatic germ cell tumours. 
The Chemo & Cognition study opened in 2007 at four Australian sites, with funding 
support from the Cancer Council. The objective of this longitudinal observational study is 
investigation of cognitive impairment in men with testicular cancer. The study has been 
designed to minimise the methodological problems of previous studies. 
ANZGCTG TRIALS
Trial Participants Interventions Main outcome 
measures
Status
Accelerated BEP: feasibility study of accelerated 
BEP as ﬁ rst-line chemotherapy for advanced 
germ cell tumours
An intergroup collaboration between ANZGCTG 
and ANZGOG
Patients with intermediate and 
poor-risk advanced germ cell 
tumours (and selected good-risk  
tumours).
Bleomycin, 
etoposide, cisplatin, 
pegﬁ lgastrim
• feasibility
• safety
• eﬃ  cacy 
• lung function
• neurotoxicity
Recruitment target: 
25
Open to recruitment
Chemo & cognition: cognitive function and 
treatment for testicular cancer
Patients being treated and followed 
up for testicular cancer
Non-interventional 
study
• cognitive function Recruitment target: 
154
Open to recruitment
Amy Boland 
ANZGCTG trial coordinator
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A BETTER FUTURE FOR NEWBORNS
A  B E T T E R  F U T U R E  F O R  N E W B O R N S
INIS: preventing the damaging eﬀ ects of 
neonatal infection
Newborn infants, particularly those born prematurely, have an immature immune system 
and so are at risk of infection. Infection can cause inﬂ ammation in major organs, resulting in 
death or permanent disability. Each year, of over 2500 babies in Australia and New Zealand 
who develop serious infection, about 250 die and another 375 survive with lifelong disability. 
The International Neonatal Immunotherapy Study (INIS) is a major international, double-
blind, placebo-controlled randomised trial of polyclonal immunoglobulin (IVIG) added to 
antibiotic therapy for newborn infants with serious infection. 
In the INIS trial, infants with low birthweight and suspected serious infection have received 
infusions of IVIG (Intragam P) or saline. The main outcome being measured is survival 
without major disability at 2 years, corrected for gestational age. 
The trial has 24 centres in Australia and New Zealand actively participating. INIS ﬁ nished 
recruitment in May 2007. The Australian and New Zealand cohort of 1398 babies was 40% 
of the global recruitment total of 3493 babies. As recruitment has ﬁ nished, the focus of trial 
operation is on gathering follow-up data to assess the children’s development status. Of the 
babies in the trial, 895 have reached the two-year mark (92% of these have already been 
followed up) and 1202 have reached one year.
FUNDING FOR INIS
United Kingdom Medical 
Research Council, 
Sydney University Sesqui grant, 
Telstra Foundation, 
Ian Potter travel grant, 
National Health and Medical 
Research Council, 
Financial Markets Foundation for 
Children, 
New Zealand Health Research 
Council.
Lucille Sebastian,  INIS manager
INIS
BOOST II
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BOOST II: Oxygen therapy for premature babies
Each year, over 600 infants born at less than 28 weeks gestation are discharged from 
hospitals in Australia. Although they have a fairly normal life expectancy, they are at risk 
of disease and disability, such as chronic lung disease, poor growth, visual deﬁ cits, cerebral 
palsy, sensory disabilities and cognitive impairment.
Oxygen is has long been a common therapy. But uncertainty about the best level of 
oxygenation for extremely preterm infants has existed for over 50 years. Levels of oxygen in 
a lower range may increase rates of heart abnormalities and lung disease, and impair brain 
development; levels in a higher range may increase blindness and lung disease, and impair 
brain development. 
The CTC’s BOOST II trial (Beneﬁ ts of Oxygen Saturation Targeting) is one of several large 
trials around the world aiming to ascertain which of two currently used ranges of oxygen 
saturation is better for very premature babies. Infants are randomised to one of two target 
oxygen saturations, and receive oxygen therapy for several weeks, until 36 weeks corrected 
gestation, when they can breathe air.
The trial is in the recruitment phase. Recruitment has been steady and is expected to reach 
its target by 2009. 
Participants: 
Neonates born before 28 weeks 
gestation
Intervention:
• supplementary oxygen to 
85–89% saturation
• supplementary oxygen to 
91–95% saturation
Outcome measures:
• death or survival with major 
disability at 2 years
• retinopathy of prematurity
• chronic lung disease
Recruitment target: 1200
Recruitment: 397
Funding: NHMRC
META-ANALYSIS OF 
NEONATAL TRIALS
The ﬁ rst prospective meta-analysis 
in neonatology is the international 
Neonatal Oxygenation Prospective 
Meta-analysis (NeOProM) (p. 30).
BOOST II is one of ﬁ ve trials 
evaluating the best level of 
oxygenation for extremely preterm 
infants. The group expects to have 
ﬁ nal data from about 5200 infants 
by 2013.
Alpana Ghadge
 BOOST II manager
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REDUCING CARDIOVASCULAR DISEASE MORTALITY
The international FIELD trial: aiming to reduce 
complications of diabetes
The CTCs FIELD (Fenoﬁ brate Intervention and Event Lowering in Diabetes) trial, with 9795 
patients in Australia, New Zealand and Finland, aimed to prevent cardiovascular events in 
patients with diabetes by using fenoﬁ brate to modify blood lipids.
Since publication of the main ﬁ ndings in The Lancet in 2005, the FIELD team has been 
working on research and further publications investigating diﬀ erent subsets of the FIELD 
cohort — as was planned in the trial protocol. FIELD also continues with long-term follow-
up of all surviving patients.
In 2007, the FIELD investigators reported, in a Lancet paper, that treatment with fenoﬁ brate 
reduces the need for laser therapy for diabetic eye disease (see research highlights, p. 10). 
A substudy of patients from the FIELD Helsinki cohort showed that fenoﬁ brate changes the 
distribution of cholesterol particles in the blood. It did not aﬀ ect the level of high-density 
lipoprotein (HDL) cholesterol; however, it reduced the proportion of larger particles (HDL3) 
and increased the proportion of small, dense HDL particles. Fenoﬁ brate also reduced the level 
of very low-density lipoprotein (VLDL) cholesterol particles all of which should favourably 
aﬀ ect the risk of cardiovascular events. 
A meeting between the management committee members and Australian principal 
investigators in December 2007, sponsored by Solvay and hosted by the CTC, brought forth 
new ideas and avenues for further research. 
FIELD staﬀ : Anthony Keech (FIELD study 
chair), Dana Tse, Mark Donoghoe, Diana 
Zannino, Merryn Voysey, Rachel O’Connell
FIELD TRIAL
LIPID TRIAL
ASPIRE TRIAL 
AND INSPIRE META-ANALYSIS
VIGOUR COLLABORATION
HERO-2
R E D U C I N G  C A R D I OVA S C U L A R 
D I S E A S E  M O R TA L I T Y
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LIPID cholesterol lowering trial: 15 years on
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) trial was the 
CTC’s ﬁ rst large, long-term multicentre trial. After the end of the trial in 1997, about 85% of 
patients continued on lipid-lowering therapy. 
Patients are still being followed up by letter and telephone, and other data come from 
searches of registers of morbidity, mortality and cancer.  Now, after over 15 years of follow-
up of these patients, the information is being used to assess the long-term safety and cost-
eﬀ ectiveness of pravastatin treatment.
The size and longevity of the LIPID study data set provide a rich source for research on the 
eﬀ ects of lipid-lowering treatment and the relationships between patients’ characteristics, 
their risks and their subsequent cardiovascular events. During 2006, the results of an 
assessment of the long-term safety of pravastatin treatment, especially with regard to the 
incidence of new cancers, were presented. Also, a study describing the cost-eﬀ ectiveness of 
pravastatin use by elderly patients was published.
GENOMIC STUDIES
The LIPID trial continues to provide new data for study. Blood samples collected over the 
ﬁ rst six years of the trial are now being analysed in relation to biomarkers and risk factors for 
cardiovascular disease (p. 42). As these are biological as well as clinical investigations, they 
are being conducted in collaboration with new partners from various parts of Australia and 
the rest of the world — currently Germany, Sweden and the United States.
PRAVASTATIN AND 
COENZYME Q10
The mechanism of action of 
pravastatin and its relation with 
coenzyme Q10 was explored in 
a prospectively planned study 
of blood plasma samples from 
patients who subsequently died 
from cardiovascular disease or had a 
myocardial infarction or stroke. 
This substudy was published in 2006.
The LIPID team: Helen Pater (project 
manager), Wendy Hague (manager of LIPID 
in the 1990s and now director of the CTC’s 
clinical trials program), Adrienne Kirby and 
Liz Barnes (LIPID statisticians)
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REDUCING CARDIOVASCULAR DISEASE MORTALITY
PREDICT SUBSTUDY
PREDICT is a substudy of the ASPIRE 
trial, its purpose a simple clinical 
prediction model for a patient’s 
risk of recurrent VTE. The model 
uses a combination of patient 
characteristics with an estimate of 
residual thrombosis from the earlier 
episode measured by compression 
ultrasound and D-dimer (a test for 
detecting fragments of blood clot in 
the blood). Patients found to be at 
low risk of VTE may then be able to 
avoid warfarin treatment and its 
side-eﬀ ect — bleeding.
As part of ASPIRE, PREDICT is much 
more eﬃ  cient and cost-eﬀ ective than 
it would be as a stand-alone study.
PREDICT is supported by a grant 
from the Australasian Society of 
Thrombosis and Haemostasis and 
the National Heart Foundation. 
Using aspirin to prevent recurrent venous 
thrombosis: the ASPIRE trial and the INSPIRE 
meta-analysis
The aim of ASPIRE is to determine whether aspirin is better than placebo in preventing 
recurrent venous thromboembolism (VTE) in patients who have been treated for an earlier 
VTE with warfarin for at least 6 months. The trial is to recruit 2000 patients from Australia, 
New Zealand, Singapore, India and European countries. 
The ﬁ rst patient was enrolled in 2003, and the main phase of the study began in January 
2005. To date, 39 centres in Australia, New Zealand and Singapore are taking part. Because 
of changes in the clinical management of venous thrombosis in Australia, recruitment has 
been less than planned. This has been managed by a modiﬁ cation to the calculations in the 
study design — facilitated by good compliance by current patients — and expansion of the 
trial to new international sites for an increase in recruitment. 
Participants
People who have had a ﬁ rst episode of unprovoked proximal deep-vein thrombosis or 
pulmonary embolism and completed anticoagulant treatment.
Study drug: low-dose acetylsalicylic acid (aspirin)
Main outcome measures
• venous thromboembolism or fatal pulmonary embolism
• vascular events (cardiovascular death, symptomatic venous thromboembolism, 
myocardial infarction or stroke) 
• net clinical beneﬁ t (death, major vascular event or major bleeding)
Recruitment target: 2000
Recruitment: 478 from Australia, New Zealand and Singapore
Funding: NHMRC, Bayer, Australasian Society of Thrombosis and Haemostasis, New 
Zealand Health Research Council
Sarah Chinchen, trial monitor, and Rebecca Mister, manager of ASPIRE
6
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MEMBERS OF VIGOUR
• NHMRC Clinical Trials Centre, University of Sydney, Australia
• Duke Clinical Research Institute, Duke University, North Carolina, USA
• Cleveland Clinic Foundation, Cleveland, Ohio, USA
• Duke Clinical Research Institute of Pharmacy, Duke University, 
North Carolina, USA
• Green Lane Coordinating Centre, Green Lane, Auckland, New Zealand
• Flinders Coordinating Centre, Adelaide, South Australia
• Flinders Clinical Trial Pharmacy, Adelaide, South Australia
• Leuven Coordinating Centre, University Hospital, Gasthuisberg, Leuven, Belgium
• Canadian Coordinating Centre, University of Alberta, Alberta, Canada
• Latin American Coordinating Centre, Rosaria, Argentina
STATISTICAL ANALYSES FOR 
THE HERO-2 TRIAL
The HERO-2 trial (Hirulog and Early 
Reperfusion or Occlusion) compared 
two antithrombosis treatments for 
acute myocardial infarction in 17 073 
patients in 46 countries. The large 
data set continues to be the source 
of new ﬁ ndings from the analyses at 
the CTC. 
A study published in 2007 examined 
the survival of patients who suﬀ ered 
a reinfarction after admission to 
hospital for a ﬁ rst infarction. Patients 
who had a reinfarction had 2.4 times 
the mortality rate of patients who did 
not. The detailed statistical analysis 
showed that various factors were 
related to higher mortality, including 
lack of reperfusion therapy for the 
second infarction. Treatment by drug 
therapy or percutaneous coronary 
intervention was shown to have 
been under utilised, particularly in 
non-Western countries.
National coordinating centres have been set up in the United Kingdom and India. 
Preparation Agreements, ethical and regulatory submissions and feasibility surveys 
commenced in 2007 in preparation for recruiting 350 patients per year at, ultimately, 20 
sites in the UK (coordinated at Queen Mary University in London) and 10 sites in India 
(coordinated at St John’s Medical College and Research Institute in Bangalore). 
European patients have been included through collaboration with the Italian investigators of 
the WARFASA study, who have recruited over 300 patients from 38 sites, bringing the total 
recruitment to almost 800 patients. The ASPIRE and WARFASA investigators have agreed to 
combine their data in a prospective meta-analysis, INSPIRE.
VIGOUR collaboration
VIGOUR (the Virtual Coordinating Center for Global 
Collaborative Cardiovascular Research) is an international 
alliance of investigators from academic institutions 
undertaking clinical trials on treatments of patients having  
acute cardiovascular events, such as myocardial infarction 
and stroke.
As part of the VIGOUR collaboration, the CTC is able to 
take part in large trials which are beyond the capacity of 
Australian investigators alone. Professor John Simes is a 
VIGOUR leader.
The CTC is the  global statistical centre for VIGOUR’s 
international HERO-2 trial.Statistical analyses for the 
HERO-2 trial.
Rachel O’Connell 
Biostatistician for HERO-2 
studies
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COMBINING TRIALS FOR OPTIMAL EVIDENCE
PERINATAL META-ANALYSES
CANCER
CARDIOVASCULAR DISEASE
USING THE POWER OF MULTIPLE TRIALS 
IN META-ANALYSIS
Combining the results of individual trials in a meta-analysis is a well-established method of 
clarifying the eﬀ ects of a treatment. But reanalysis of the raw data from individual patients in 
all the trials is better: it maximises the use of the data, improving its quality, and increasing 
the range and power of the analyses. Such projects require cooperation and collaboration 
among trial groups as well as the resources to extract and analyse the data and to coordinate 
the group.
Even more powerful is prospective meta-analysis, in which the hypotheses and analyses 
for the combined data are planned before any trial results are available. The investigators 
agree to pool their future data. Ideally, these decisions are made early, during the conception 
and design stage of the trials. Prospective meta-analysis is considered the ‘gold standard’ 
systematic review method. It provides the same strengths as a single large-scale randomised 
trial, but can be easier to put into practice. 
The CTC is a member of several international meta-analysis groups and is a leader in 
prospective meta-analysis methodology. During the past two years, preparatory work for 
several new studies — especially in neonatal and perinatal medicine — has been undertaken 
by the CTC and its international collaborations. 
Perinatal meta-analyses
APPROPRIATE LEVELS OF OXYGEN SATURATION FOR EXTREMELY 
PRETERM INFANTS
The Neonatal Oxygenation Prospective Meta-analysis (NeOProM) Collaboration has been 
formed to undertake a prospective meta-analysis of data from about 5200 patients in ﬁ ve 
trials to answer the important clinical question of the best level of oxygenation for extremely 
preterm infants. This will be the ﬁ rst prospective meta-analysis in neonatology.
A collaborative group was formed in 2003 and the ﬁ rst participating trial, the CTC’s BOOST 
II, (p. 25), started enrolling patients in 2005. The protocol for the meta-analysis currently 
being ﬁ nalised. Results should be available in 2013. 
ANTIPLATELETS FOR PREVENTION OF PRE-ECLAMPSIA 
AND ITS CONSEQUENCES
There has been good evidence from clinical trials and meta-analysis that antiplatelet agents 
(principally low-dose aspirin) prevent pre-eclampsia, a leading cause of morbidity and 
mortality in pregnant women and their babies. Uncertainty remains about whether some 
women beneﬁ t more than others, what dose of aspirin is best and when in pregnancy 
treatment should start. Rather than undertaking new trials, the best way to answer these 
questions is to utilise existing data from each trial. 
CO M B I N I N G  T R I A L S 
F O R  O P T I M A L  E V I D E N CE
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In the ﬁ rst individual-patient-data review in the perinatal ﬁ eld, data from 38 000 women 
were collected from 38 eligible trials by the PARIS (Perinatal Antiplatelet Review of 
International Studies) Collaboration. The study showed that therapy with antiplatelet agents 
is safe, and reduces (by about 10%) the relative risk of pre-eclampsia, preterm birth, and 
serious adverse outcomes of pregnancy. No subgroups were identiﬁ ed as beneﬁ ting more 
or less from the treatment. Especially for populations with a high risk of pre-eclampsia, the 
more widespread use of antiplatelet agents would be worthwhile. 
The results were published in The Lancet in 2007. Analysis of the dataset at the CTC is 
continuing.
BENEFITS AND RISKS OF ELECTIVE HIGH-FREQUENCY VENTILATION 
VERSUS CONVENTIONAL VENTILATION IN PRETERM INFANTS WITH 
RESPIRATORY DISTRESS SYNDROME
After 18 trials enrolling more than 3500 infants with respiratory distress, the eﬀ ect of 
high-frequency ventilation is still uncertain. An analysis of data from these trials by the 
international Prevention of Ventilation-Induced Lung Injury Collaborative Group (PreVILIG) 
will take into account the risk proﬁ les of the infants and identify the characteristics of the 
infants most likely to beneﬁ t from the treatment.
INHALED NITRIC OXIDE FOR PRETERM INFANTS
Premature infants requiring assisted ventilation are at risk of injury to their lungs and brains. 
Inhaled nitric oxide may help, but the results of trials so far have been contradictory. Some 
studies have shown a reduction in lung injury, one has shown a reduction in brain injury, 
and several others have shown no eﬀ ect. The diﬀ erent patient characteristics and diﬀ erent 
trial characteristics may explain this diﬀ erence. Collection and reanalysis of data from about 
2500 individual patients in the nine trials will commence in 2008, in a collaboration with 
neonatologists in the US and Canada.
Deﬁ nitive evidence from meta-analyses 
of data from cancer trials
Meta-analyses of data from published cancer trials have provided 
new evidence to guide treatment. 
OESOPHAGEAL CANCER
Patients with oesophageal cancer are usually treated with surgery, 
but outcomes can be poor. Chemotherapy or chemoradiotherapy 
may be given before surgery but whether this is beneﬁ cial has not 
been clear because trials have been small and have not had adequate 
statistical power. 
Dr Lisa Askie is a world leader 
in individual-patient-data 
meta-analysis in perinatology. 
She is the project coordinator of 
the PARIS Collaboration, project 
coordinator and co-chair of the 
NeOProM Steering Group, and 
a member of the MAPPiNO and 
PreVILIG steering groups.
No. patients Hazard ratio
Study Year Chemo- Surgery with 95%
radiotherapy alone confidence interval
Nygaard 1983 53 25
Apinop 1986 35 34
LePrise 1988 45 41
Bosset 1989 148 145
Urba 1989 50 50
Walsh 1990 58 55
Burmeister 1994 128 128
Lee 1999 51 50
Walsh 1990 29 32
Tepper 2006 30 26
All 627 586
0.2 0.5 1 2 5
favours
chemoradiotherapy
favours
surgery alone
       
32 NHMRC CLINICAL TRIALS CENTRE: 2006–2007 RESEARCH REPORT
COMBINING TRIALS FOR OPTIMAL EVIDENCE
Despite eight previous published meta-analyses, this research addressed survival beneﬁ ts 
in a new way by incorporating all the information available from the studies and by 
examining clinical subgroups. Analysis of results from 17 trials showed a clear beneﬁ t of 
chemoradiotherapy, but a less certain beneﬁ t in adenocarcinoma than in squamous cell 
carcinoma.
These results were published in The Lancet Oncology in 2007.
BREAST CANCER
A review of randomised trials examined the beneﬁ ts of postmastectomy radiation therapy. 
The method involved incorporating the quality of the individual trials in the meta-analysis 
to obtain estimates of beneﬁ t which reﬂ ect clinical practice more closely (Research 
highlights, p. 12).
Cardiovascular disease
PRIMARY CORONARY ANGIOPLASTY VERSUS THROMBOLYSIS: 
THE PCAT COLLABORATION
For patients who have arrived at a hospital shortly after a myocardial infarction caused by a 
blocked coronary artery, the most eﬀ ective treatment is mechanical opening of the artery by 
an operation involving a balloon or stent. However, it takes time to arrange for the procedure 
and prepare the patient, in addition to any delay in the patient reaching hospital. Restoring 
the blood ﬂ ow with drugs is less likely to be successful, but can be done more quickly. 
In an international study, the investigators pooled and reanalysed data from 6763 patients 
in 22 trials comparing primary percutaneous coronary intervention with ﬁ brinolytic drug 
therapy, taking into account the delays between the onset of symptoms and treatment. The 
outcome measured was mortality after 30 days. 
Mortality was lower in those who had the mechanical procedure even if the treatment 
was delayed. However, its advantage was greater for patients who were slow to present to 
hospital, and lesser with a longer delay between reaching hospital and having the procedure. 
Although the study showed that percutaneous coronary intervention results in lower 
mortality, in the real world, where timely intervention may not be available, drug therapy is 
still a viable treatment strategy.
The results underlined the importance of early hospital treatment for all patients who have 
had a myocardial infarction. The study was also an example of using published data and 
precise analysis techniques to arrive at new authoritative evidence. 
LONG-TERM CHOLESTEROL LOWERING WITH STATINS
The Cholesterol Treatment Trialists’ Collaboration (CTTC) was ﬁ rst formed in 1990, before 
the results of various large international trials showed that cholesterol-lowering therapy 
with statins reduced the risk of death from coronary heart disease. The purpose of the 
collaboration is prospective meta-analysis of data from 14 constituent clinical trials involving 
over 90 000 patients. The protocol for its studies was published in 1995, and the ﬁ rst 
analysis of results appeared in 2005.
In 2007, the collaboration presented the results of the subgroup analyses of data from 
18 686 patients with diabetes in these trials. Statin therapy reduced the risk of vascular 
events consistently in all the studied subgroups of patients with diabetes, even in patients 
with type 1 diabetes and those who had not previously had any cardiovascular disease.
John Simes
Co-chair of the international 
PCAT Collaboration
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Biostatistics is fundamental to 
clinical trials research
CLINICAL TRIALS
As new concepts are proposed by trial groups, biostatisticians at the CTC develop trial 
designs most likely to answer the questions presented. The collaborative trial groups include 
national experts trialling new therapies in gastrointestinal cancer (colorectal, stomach and 
oesophagus), breast cancer, gynaecological cancer (cervix, ovarian), neonatal disorders, 
diabetes, cardiovascular disease and thrombosis. The statistical designs include single-arm 
and randomised phase II designs and randomised phase III designs.
Biostatisticians monitor ongoing trials (including triggers for interim analyses, such as the 
activity of the investigational regimen and the rate of severe toxicity), develop statistical 
analysis plans and prepare and interpret statistical reports for independent data safety and 
monitoring committees. They also contribute to and oversee the science for presentations 
at national and international conferences. Presentations include reports on the eﬀ ect of 
sentinel-lymph-node biopsy on lymphodoema rates in breast cancer (SNAC, p. 13), toxicity 
and beneﬁ ts of chemotherapy treatments in colorectal (p. 11) and biliary tract cancers 
(p. 18), and fenoﬁ brate in patients with diabetes mellitus (p.26).
RANDOMISATION
Methods of randomisation are continually evolving. The biostatistics group 
designs randomisation schemes, such as permuted blocks, minimisation and 
dynamic balancing, provides unblinding services for double-blind studies and 
monitors the balance of allocations between treatments. Randomisation 
schemes are implemented via the internet or via telephone calls in an 
interactive voice response system (IVRS). For some studies, there is also 
an element of randomisation ‘shadowing’, in which allocations provided 
electronically are validated manually.
EDUCATION
The CTC is intimately involved in the Biostatistical Collaboration of Australia 
(p.9). Additionally, CTC biostatisticians coordinate the unit ‘Controlled trials’ 
oﬀ ered in the Master of Clinical Epidemiology and Master of Public Health 
programs at the University of Sydney. A two-day course in clinical trials 
methods and interpretation, for potential clinical and research investigators 
and triallists, is regularly run by the CTC. Ongoing units in the Basic Sciences in 
Oncology course teach critical appraisal to medical specialist trainees. Senior 
CTC biostatisticians supervise students doing projects as part of the Master of 
Biostatics degree or other higher degrees (MSc or PhD). 
I M P R OV I N G  T H E  A N A LYS I S  A N D 
CO N D U C T  O F  CL I N I C A L  T R I A L S
BIOSTATISTICS
METHODOLOGICAL 
RESEARCH PROJECTS
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Adrienne Kirby, 
senior biostatistician
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IMPROVING THE ANALYSIS AND CONDUCT OF CLINICAL TRIALS
Some methodological research projects
RISK FACTOR DEVELOPMENT AND VALIDATION
The data from the international studies HERO-2, with 17 073 patients (p. 29), and FIELD, 
with 9795 patients (p. 26), has been used to compare diﬀ erent methods of updating risk 
models for their suitability and applicability in countries with vastly diﬀ erent cultures and 
health care systems. This work has been led by Rachel O’Connell and Malcolm Hudson in 
a team that includes PhD students.
Related methodological projects include the evaluation of biomarkers as predictors of 
outcome. This includes evaluating the strength of biomarkers as potential surrogates in 
relation to outcomes, as well as the interaction between potential surrogates and treatment
SAMPLE SIZE FOR TRIALS WITH ALTERNATIVE OUTCOMES
Calculating the number of patients needed for a clinical trial and the power of a proposed 
analysis is part of the work of biostatisticians. When more than one outcome is of prime 
importance, the computations become complex. CTC biostatisticians have developed 
solutions which can accommodate diﬀ erent adjusted critical signiﬁ cance levels (α) for 
multiple outcomes while maintaining a ﬁ xed overall level of signiﬁ cance. An advantage of 
this new method is that the power of detecting a diﬀ erence of a given size is maintained. 
In trials with two or three alternative outcomes which are not highly correlated with each 
other (< 0.8), a simple Bonferroni adjustment is conservative and is closer to the exact 
solution than other ad hoc approximations currently in use. 
These new looks at old problems were presented at the International Clinical Trials 
Symposium.
ANALYSIS OF TIME SERIES DATA
Automated logging devices can collect real-time data from patients, which leads to a large 
number of data points over time for each patient. Other more traditional methods, such 
as daily diaries, also give rise to time series of measurements. Analysis of multivariate non-
stationary time series poses a real challenge to statisticians. An account of some of the issues 
involved has been published in the Australian and New Zealand Journal of Statistics in an 
article illustrating the concepts with associations between daily changing pollen counts and 
eye and nasal symptoms, together with the eﬀ ect of having asthma.  
Short time series of measurements within subjects often arise in the context of clinical trials. 
Linear mixed-eﬀ ects models can be used to quantify treatment eﬀ ects in such situations. This 
approach was used to investigate changes in bone mineral density in patients treated with 
placebo or zoledronic acid to prevent bone loss after liver transplantation, recently published 
in the Annals of Internal Medicine. 
MIXED LINEAR MODELS: ROBUST ALTERNATIVES TO THE F TEST 
Mixed linear models are popular and used to analyse data in many ﬁ elds. The models are 
usually ﬁ tted by maximum-likelihood techniques that rely on the data distribution being 
normal. The estimates of the parameters and the related tests are very sensitive to the 
assumption of normality. This sensitivity can lead to incorrect conclusions. In this study, 
published in Biometrics, biostatisticians developed two robust methods to overcome this 
problem by computing an alternative to the F test. The ﬁ rst method is a likelihood-based 
approach and the second is an extension of the Wald statistic. Both have been tested by 
simulation and both are suitable for balanced study designs.
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NEW TECHNOLOGIES, 
DIAGNOSTIC TESTS AND PROCEDURES
SYSTEMATIC REVIEWS AND THE 
COCHRANE COLLABORATION
THE AUSTRALIAN NEW ZEALAND 
CLINICAL TRIALS REGISTRY
Assessment of new technologies, 
diagnostic tests and procedures
The CTC has a contract to review new and existing health technologies, diagnostic tests and 
procedures for the Australian Government’s Medical Services Advisory Committee (MSAC). 
The government’s intention is that evidence of safety, eﬀ ectiveness and cost-eﬀ ectiveness, 
obtained through systematic reviews and health-economic analyses, should underpin public 
funding of medical procedures. Each report is based on a systematic review of the scientiﬁ c 
literature and other information sources, including clinical expertise. The reports 
are published on the MSAC’s website.
BREAST MAGNETIC RESONANCE IMAGING
Breast magnetic resonance imaging (MRI) can be used in screening for and diagnosis of 
breast cancer. 
The addition of breast MRI to mammography improves the detection of breast cancer — 
but also the rate of false detections of cancer — in young women at high risk due to genetic 
predisposition or family history. It is still not known whether the earlier detection of breast 
cancer in this patient group improves their outcomes. Interim public funding for breast MRI 
was recommended for the diagnosis of breast cancer in women at high risk, when it is used 
as part of an organised surveillance program. 
The Gamma Knife review was presented as 
a poster at the International Clinical Trials 
Symposium
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NATIONALLY FUNDED CENTRES
The CTC, through its contract with MSAC, provided the Australian Government with 
reviews of evidence for nationally funded centres, which provide Australians with 
equitable access to rare, costly medical technologies or procedures. 
Peritonectomy
Peritonectomy is treatment for peritoneal tumours (pseudomyxoma peritonei and 
peritoneal mesothelioma). The surgical procedure is performed in combination with 
intraperitoneal chemotherapy and is often followed by further local and systemic 
chemotherapy. The review identiﬁ ed only poor-quality studies which did not compare 
peritonectomy with alternative procedures. It was considered that conducting the 
procedure in a single centre may have safety advantages. It was recommended that 
one centre should undertake research and evaluation to determine the eﬀ ectiveness of 
this service in the longer term.
Selective dorsal rhizotomy
Selective dorsal rhizotomy is an operation on the spinal nerve rootlets to treat 
spasticity in the lower limbs in children with cerebral palsy. It involves extensive 
preoperative investigations, including gait analysis, and a postoperative rehabilitation 
program.
The review found that rhizotomy plus physiotherapy improves spasticity and general 
motor function, compared with physiotherapy alone. Establishing one nationally 
funded centre was recommended, along with development of national protocols and 
collection of long-term follow-up data to allow for monitoring of adverse events.
Pulmonary thromboendarterectomy
Pulmonary thromboendarterectomy (PTE) is an operation for removing blood clots 
that obstruct blood ﬂ ow to the lungs. PTE is a high-risk procedure involving heart–lung 
bypass. This review showed that the procedure could improve function and blood 
ﬂ ow and concluded that it may substantially beneﬁ t patients. Establishing a nationally 
funded centre was recommended.
Paediatric liver transplantation
Paediatric liver transplantation is the only treatment available for children with acute 
liver failure or end-stage liver disease. The review found that survival results from three 
existing Australian centres compared well against international data. It was found that 
demand for transplantation could be met by a single centre, but two centres would be 
appropriate to ensure equity of access. Development of paediatric liver transplantation 
management guidelines, improved data collection, and surgical workforce succession 
planning were also recommended.
EVIDENCE-BASED DECISIONS 
ABOUT USING NEW TESTS
The clinical value of a new test 
depends on whether it improves 
patient outcomes. Cases of disease 
detected by new tests are rarely 
evaluated by clinical trials, so 
decisions about their use often rely 
on studies of test accuracy. But is this 
enough?
In their publication, ‘When is 
measuring sensitivity and speciﬁ city 
suﬃ  cient to evaluate a diagnostic test, 
and when do we need randomised 
trials?’ Sally Lord and her co-authors 
explain the assumptions required if 
evidence about test accuracy is to be 
used to plan treatment. They describe 
a useful framework for deciding when 
this evidence will suﬃ  ce.
Sally Lord
Suzanne Dyer
9
       
 NHMRC CLINICAL TRIALS CENTRE: 2006–2007 RESEARCH REPORT 37
 
 
 
 
 
 
 
Systematic reviews and 
the Cochrane Collaboration
Systematic reviews follow rigorous methods to search for all clinical trials on a particular 
topic and then to combine that information into summaries of the best available evidence.
The Cochrane Collaboration is the largest organisation in the world engaged in the 
production and maintenance of systematic reviews of health care interventions. The 
Cochrane Library publishes the reviews of over 50 specialist groups, one of which is the 
Cochrane Breast Cancer Group, based at the CTC. This group coordinates almost 200 authors 
who prepare accurate and up-to-date reviews on all aspects of breast cancer (box).
The group edits the reviews, maintains a specialised register of over 8000 references to trials 
in breast cancer, advises on methodological and clinical content and facilitates peer review. 
The Cochrane Breast Cancer Group is supported by the Commonwealth Department of 
Health and Ageing. 
RECENT  REVIEWS COORDINATED AND EDITED AT  THE CTC:
• Compared aromatase inhibitors and other endocrine therapy, ﬁ nding that in women 
with advanced breast cancer, survival was better with aromatase inhibitors.
• Assessed the eﬀ ectiveness and safety of Chinese medicinal herbs in alleviating side-
eﬀ ects of chemotherapy. The herbs may oﬀ er some beneﬁ t to breast cancer patients in 
terms of bone marrow improvement and quality of life. 
SCOPE OF THE REVIEWS 
OF THE COCHRANE 
BREAST CANCER GROUP
Prevention 
• physical activity 
• breast feeding 
• dietary prevention 
• endocrine prevention 
• prophylactic surgery
Early detection 
• screening methods (mammography, 
breast self-examination, 
clinical breast examination, 
genetic screening)
• participation in screening 
Diagnosis 
• pathology 
• investigations
Management 
• chemotherapy (ductal carcinoma 
in situ (DCIS), locally advanced 
and advanced disease)
• complementary and alternative 
therapies (herbal medicine, 
homeopathy, traditional Chinese 
medicine), diet and physical therapies 
(acupuncture, chiropractic, manual 
therapy, massage)
• endocrine therapy (DCIS, locally 
advanced and advanced disease)
• immunotherapy (DCIS, locally 
advanced and advanced disease)
• psychosocial interventions 
• radiotherapy (DCIS, locally advanced 
and advanced disease)
• supportive care 
• surgery (curative and plastic surgery)
• prevention and management of 
treatment-related adverse events 
and side-eﬀ ects related to surgery, 
chemotherapy, radiotherapy
Familial breast cancer 
Rehabilitation and otherSharon Parker and Nicole Holcroft
Cochrane systematic reviews are available at:
www3.interscience.wiley.com/cgi-bin/rwhome/106568753/home
»
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• Assessed the eﬀ ect of exercise during treatment for breast cancer. Improvements in 
fatigue were ambiguous and any improvement in other treatment-related side-eﬀ ects 
lacked evidence.
• Assessed the eﬀ ectiveness of chemotherapy before, rather than after, surgery for breast 
cancer. Preoperative chemotherapy did not make a diﬀ erence to survival time, but it had 
some advantages, such as reducing the size of the tumour to be removed.
• Assessed the value of mammography screening. The review showed that screening 
reduces breast cancer mortality but also results in diagnosis and treatment of some 
conditions that may not have progressed to cancer. Women need to be informed of the 
possible consequences of screening.
• Investigated the sequencing of chemotherapy and radiotherapy in early breast cancer. 
Diﬀ erent  sequences appeared not to have a major eﬀ ect on survival or recurrence if 
radiation therapy commenced within 7 months of surgery.
• Compared surgery (with or without adjuvant tamoxifen) with tamoxifen alone for 
women aged over 70 years, ﬁ nding that surgery controls breast cancer better than 
tamoxifen, but does not extend survival. Tamoxifen alone should be oﬀ ered only to 
women with hormone-responsive tumours who are unﬁ t for surgery. 
• Reviewed genetic risk-assessment services and also reviewed of  the eﬀ ectiveness of 
diﬀ erent methods to communicate a primary diagnosis of breast cancer to women. 
Both found that adequate evidence to answer the review questions was not available.
In addition to its editorial and coordinating function, the CTC group has recently completed 
its own reviews to answer questions about breast cancer treatment.
• From studies totalling 21 191 women with early breast cancer, it was found that adjuvant 
chemotherapy that included a taxane reduced the risk of death and the number of cancer 
recurrences, compared with non-taxane regimens.
• A review asked the question: Is there is any beneﬁ t to increasing the intensity of a 
treatment regimen for metastatic breast cancer, particularly given the potential harm 
caused by more dose-intensive treatment? This review investigated the value of adding 
more chemotherapy drugs to a regimen, with the ﬁ nding that this did improve the 
response of the tumour. There was insuﬃ  cient evidence to determine the eﬀ ect on 
overall survival.
Nicholas Wilcken and Davina Ghersi, co-coordinating editors of the 
Cochrane Breast Cancer Group 
TRANSFERRING EVIDENCE 
INTO PRACTICE
Members of the Cochrane Breast 
Cancer Group undertook a systematic 
review, Trastuzumab for HER2 positive 
breast cancer, for the National Breast 
and Ovarian Cancer Centre. 
This review was used for the 
NBOCC’s clinical practice guidelines: 
Recommendations for use of 
trastuzumab (Herceptin) for the 
treatment of HER2-positive breast 
cancer. 
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The Australian New Zealand 
Clinical Trials Registry
DEFINITION OF RESEARCH 
TO BE REGISTERED AS A TRIAL
Any research study that 
prospectively assigns 
human participants or 
groups of humans to one 
or more health-related 
interventions to evaluate 
the eﬀ ects on health 
outcomes.
— International Committee of Medical 
Journal Editors and World Health 
Organization
Some of the staﬀ  of the ANZCTR: 
Fergus Tai, Lisa Askie, Nicole Holcroft 
and Thuyen Vu, with Jenny Chow, 
executive oﬃ  cer for Systematic Reviews 
and Health Care Assessment
The Australian New Zealand Clinical Trials Registry (ANZCTR) is an on-line, prospective 
register of clinical trials. It captures trials being conducted in Australia, New Zealand and the 
neighbouring region, with representation as well from far-ﬂ ung countries in Europe, Asia 
and North and South America. All data required by the registry and submitted by the sponsor 
are publicly available. Registration of trials is expected to lead to more eﬃ  ciency and less 
duplication of research and less bias in the publication of clinical evidence. 
The ANZCTR is a primary register of the World Health Organization and is recognised by the 
International Committee of Medical Journal Editors. It is part of a worldwide system in which 
anyone looking for trials related to a certain condition can access a one-stop search portal, 
which provides a short list of potential trials and their details within seconds. It is also a 
source of information for patients and doctors wanting to participate in current trials. 
Since the Australian registry was ﬁ rst established in 2005, the number of trials registered has 
grown to nearly 2000: 82% of registered trials have an Australian sponsor, 11% are from New 
Zealand and 7% are from other countries. About 27% have a commercial sponsor. 
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END-OF-LIFE COMMUNICATION: 
A FOUNDATION FOR CLINICAL GUIDELINES
One of the most important aspects of medical care at the end of life is communication. 
Health professionals need guidelines on how to discuss dying, life expectancy and future symptoms with patients and their families. 
However, this is an example of a research question which does not lend itself to the method of a randomised controlled trial. A 
systematic review by the CTC, in collaboration with the Medical Psychology Unit at the University of Sydney, has now provided the 
evidence to underpin speciﬁ c guidelines and communication skills training for health professions about these sensitive and diﬃ  cult 
topics.
The review found:
• Doctors tend to underestimate patients’ needs for information. Patients are more satisﬁ ed with the overall care given if they are told 
about their situation. 
• Patients and those caring for them in English-speaking and non-English-speaking cultures can diﬀ er, although individual diﬀ erences 
are paramount. 
• Doctors and patients have diﬀ erent perceptions of the patients’ comprehension.  
• For doctors to avoid giving information can make patients feel worse. Patients are better oﬀ  if information balances honesty with 
empathy and hope.
• People caring for dying patients need to be included in communications so that they can adjust and prepare. Consistency in the 
facts, joint and separate opportunities for discussion, conﬁ dentiality and protecting patient rights are all relevant.
Australian guidelines based on this review were published as a supplement to the Medical Journal of Australia in 2007.
Registering a trial is voluntary, so currently not all Australian trials appear. Encouraging 
participation has been one focus of the eﬀ orts of the ANZCTR. One incentive is that timely 
registration is a condition of  publishing research results in major medical journals. Linking 
registration with ethics approval is another potential incentive: the recently released 
Australian National statement on ethical conduct in human research has a clause stating that 
clinical trials should be registered before participants are enrolled.
Establishing the ANZCTR has been a major milestone for trials registration in Australia. Now, 
using the beneﬁ ts of wide consultation, the registry is focusing on the scope of the required 
data, long-term sustainability, international linkages and easier accessibility (particularly via a 
project to facilitate access by cancer patients).
The ANZCTR has a high-level external advisory committee with wide representation, 
including representatives of government, research groups, consumers, the pharmaceutical 
industry, and medical journals. It is being funded, for its ﬁ rst ﬁ ve years, by the National 
Health and Medical Research Council. ANZCTR website, where researchers can 
register  trials and others can freely obtain 
information about current trials.
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Patients’ preferences 
about treatment
Cancer treatments, such as chemotherapy treatments, 
have beneﬁ ts and harms. Although clinical trials can show 
the average beneﬁ t and the average harm of a cancer 
treatment in a cohort of patients, how the treatment 
aﬀ ects an individual is not apparent from clinical trial 
evidence. 
Patients and clinicians making decisions about treatments 
need to ask: how much beneﬁ t will make the side-eﬀ ects 
and inconvenience of treatment worthwhile? 
Vlatka Duric, Martin Stockler and their colleagues have 
been doing a series of studies in which patients and clinicians are asked, to trade oﬀ  a 
treatment’s beneﬁ ts against its harms. Participants are asked to identify the smallest 
improvement in survival time or survival rate they judge necessary to make that therapy 
worthwhile. 
In the ﬁ rst studies of the series, women who had had breast cancer indicated that small 
improvements in survival were enough to make chemotherapy, radiotherapy and endocrine 
therapy worthwhile. Most participants indicated that small beneﬁ ts were suﬃ  cient to make 
the treatment worthwhile.. 
In the most recently completed study, the reasons for women’s judgments about 
chemotherapy were explored. This study, published in 2007, was the ﬁ rst to evaluate 
psychosocial motivations of preferences for adjuvant chemotherapy in early breast cancer. 
Preferences were highly variable and individual. They were associated with minimising regret, 
parenting concerns, doubts about the information provided and feeling that they had no 
choice, but they were not associated with scores for anxiety, optimism, or perceived quality 
and quantity of social support.
The study showed the importance for clinicians of asking about circumstances, attitudes, and 
preferences when sharing decision making about undertaking treatment. 
WHAT MAKES 
CHEMOTHERAPY FOR COLON 
CANCER  WORTHWHILE?
Patients’ preferences for adjuvant 
chemotherapy for early colon cancer 
and their quality of life during 
treatment are  currently being 
explored in the next study of the 
series. This also has a methodological 
component: the standard structured 
interview and a new self-
administered questionnaire are being 
compared as methods for eliciting 
this information from patients. 
Results will be available in 2008.
“As soon as there is any beneﬁ t, 
regardless of how small it is, 
I would go for it.”
— A woman who had completed 
chemotherapy for breast cancer
 Vlatka Duric
Clinical psychologist
A P P LY I N G  T R I A L  R E S E A R C H 
T O  I N D I V I D UA L  PAT I E N T S
PATIENTS’ PREFERENCES
PREDICTING RISK
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Predicting risk for individual patients
Models of risk can be used for various purposes: estimating prognostic scores for individual 
patients, identifying patients at low risk who may not require treatment, identifying patients 
at high risk who may beneﬁ t more from treatment, showing the beneﬁ t versus the harm of a 
treatment, and shedding light on how it works in the body. 
The large numbers of patients in many clinical trials make them an excellent source of 
high-quality data for risk-stratiﬁ cation models. Characteristics of patients in the study cohort 
and their relation to various outcomes can be analysed to show the typical risk factors for 
a particular outcome. For example, cardiovascular risk models predict how factors like age, 
smoking and cholesterol levels, separately or together, inﬂ uence the risk of a myocardial 
infarction or stroke. The predictive ability of a model can be assessed in two ways: by its 
ability to correctly rank patients for risk and by the ﬁ t of the predicted probabilities with the 
observed rates. 
INDIVIDUAL PATHOPHYSIOLOGY IN CARDIOVASCULAR DISEASE
LIPID trial  
In the past, CTC biostatisticians developed such a risk model from the data in the LIPID 
trial (p. 27). Current LIPID studies have a more seasoned approach and are examining 
the interplay between clinical factors, novel markers of the pathophysiological processes 
associated with atherothrombosis, and genetic factors.
These studies are testing whether, in patients with existing coronary heart disease, new 
events, such as myocardial infarction and stroke, are linked to combinations of blood 
cholesterol levels, inﬂ ammation, oxidation and thrombosis. Individual diﬀ erences in these 
factors and the eﬀ ects of lipid-lowering treatment on each are taken into account.
The analyses of the LIPID study have great signiﬁ cance for a leading worldwide health 
problem. Risk stratiﬁ cation of patients may lead to identifying individuals most likely to 
beneﬁ t from taking statin drugs, a major expense in Australian health care. Data from the 
LIPID study are also contributing to risk-factor models of the international Cholesterol 
Treatment Trialists’ Collaboration, which has a database of over 90 000 patients.
HERO-2 trial
Several biostatistical studies are making use of the data from over 17 000 patients in the 
international HERO-2 trial (p. 29). One such study is comparing the performance of model-
updating methods for application in diﬀ erent geographical regions. Simple recalibration 
(re-estimation of the intercept and slope of the linear predictor within regions) and model 
revision (re-estimation of all regression coeﬃ  cients within regions), with and without 
shrinkage, are compared with the global additive model (developed from the HERO-2 data) 
with a built-in region eﬀ ect.  The relative performance of these methods in the diﬀ erent 
geographical regions, which vary in sample size, is of primary interest.
Another compares the performance of risk models that vary in terms of required inputs, 
precision of measurement of risk factors and ease of calculation. Results of these studies will 
add to the information available for individual clinical decision making in acute coronary 
heart disease.
RISK ASSESSMENT WITH 
LIPID RISK-FACTOR SCORES
–3 points
• revascularisation  after qualifying 
event (myocardial infarction or 
unstable angina)
–1 point
• pravastatin treatment
1 point
• HDL cholesterol <1.0 mmol/L
• increase in white cell count  
1 x 109/L
• low creatinine clearance
2 points
• male sex
• obesity
• prior myocardial infarction
• angina
• revascularisation before 
qualifying event
3 points
• age 55–64 years
• history of stroke
• breathlessness
• current smoking
4 points
• diabetes mellitus
• atrial ﬁ brillation
7 points
• age 65–69 years
• multiple myocardial infarction
9 points
• aged  70 years or over
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Emma Smith, BSc(hons), MSc, PhD, senior 
project oﬃ  cer
Fergus Tai, BAppSc, research assistant
Suchaya Thongyoo, BAppSc, research assistant
Thuyen Vu, BSc, project oﬃ  cer
Systematic review projects
Sally Lord, MB BS, DipPaed, MS, FRACGP, 
manager, epidemiologist and research fellow
Henry Ko, BEng(Med)(hons), GradIEAust, project 
oﬃ  cer
Charlene Thornton, BN, GradDipMid, MSc, 
project oﬃ  cer
Wei Lei, BMed, MM, project oﬃ  cer
BIOSTATISTICS AND CONSULTING
Val Gebski, BA, MStat, associate professor and 
principal research fellow
Malcolm Hudson, BSc(hons), PhD, visiting 
professor and principal research fellow
Kew Flood, administrative assistant
Senior biostatisticians
Karen Byth, BSc(hons), MSc, PhD, DIC, CStat 
RSS, senior lecturer
Patrick FitzGerald, BAppSc, GradDipMath, 
MAppSc, PhD, senior lecturer
Peta Forder, BSc(hons), MPH, MBiostat, lecturer
Stephane Heritier, MMath, MBA, PhD, senior 
lecturer
Adrienne Kirby, BSc(hons), MSc, senior lecturer
Biostatisticians
Elizabeth Barnes, BAppSc, MStat
Christopher Brown, BSc
Samuel Copt, MEc, PhD
Alistair Merriﬁ eld, MSc, PhD
Rachel O’Connell, BMath, MMedStat
Christopher Pardy, BSc(hons)
Avinesh Pillai, BSc, MSc(hons)
Tatiana Sourjina, MD, MPH, MStat
Elizabeth Williamson, PhD
Merryn Voysey, GradDipMathStat
Diana Zannino, BSc(hons), MSc
Biostatistics Collaboration of Australia 
(BCA)
Erica Jobling, executive oﬃ  cer, Biostatistics 
Collaboration of Australia
Sarah Goodman-Jones, administrative assistant
FLEXETRIALS DATA SYSTEM
Emma Vlahos, BCom, BSc, business analyst
PUBLICATIONS
Rhana Pike, BA, GradCert, MA, ELS, senior 
publications oﬃ  cer
INFORMATION SYSTEMS
Vinod Malhotra, manager
Infrastructure
Dinh Tran, BMath, MCompSc, infrastructure 
manager
Liem Tran, BMath, GradDipCompSc, computer 
systems oﬃ  cer
Asanka Perera, BSc, computer systems oﬃ  cer
Database administration
Anh Tai Nguyen, BMath, database manager
Software engineers
Seshu Atluri, BE
Anne Foy, BSc
Jianpeng Gu, MCompSc
Ashaar Riaz, BSc, MCompSc
James Robson, BSc
Ravinder Singh, BTech
Bei Zhong, MCompSc
BUSINESS ADMINISTRATION
Kim Russell-Cooper, BA(hons), MBA, general 
manager
Cynthia Carr, BEd, HRD, human resources and 
administration manager
Margaret Edwards, personal assistant to the 
director
Suzanne Everett, BSW, human resources and 
administration coordinator
Agnes Ho, MPracAcc, ﬁ nance oﬃ  cer
Anne Madden, BA, executive oﬃ  cer
Faith Papuni, personal assistant to the deputy 
director
Doris Rattos, administrative assistant
Ayanthi Salgado LLB, MA, DipIntAﬀ , operations 
manager, ANZGOG
Bebe Sim, MAcc, CPA, ﬁ nance manager
QUALITY ASSURANCE
Phillipa Smith, BPharm(hons), MSc, adviser
Karen Pinto, DipTeach, BA, PostgradDip Psychol, 
AGITG and ANZGOG trial audit coordinator
PREFERENCES STUDIES
Vlatka Duric, BSc(hons), MPsych, PhD, clinical 
psychologist
THIRD INTERNATIONAL 
CLINICAL TRIALS SYMPOSIUM
Jenny Chow, AssocDip, project manager
RESEARCH STUDENTS
Peter Grimison, BSc(Med), MB BS(hons), FRACP, 
PhD student
Michaella Smith, BSc, MB BS(hons), MMSc, PhD 
student
ACADEMIC STAFF
John Simes, BSc(Med)(hons), MB BS(hons), MD, 
SM, FRACP, senior principal research fellow 
and professor
Anthony Keech, MB BS, MSc, FRACP, principal 
research fellow and professor
Lisa Askie, BN, MPH, PhD, research fellow
Karen Byth, BSc(hons), MSc, PhD, DIC, CStat 
RSS, senior lecturer
Vlatka Duric, BSc(hons), MPsych, PhD, associate 
lecturer
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Corona Gainford, MB BCh, BAO(hons), MSc, 
MRCP (UK), clinical research fellow
Patrick FitzGerald, BAppSc, GradDipMath, 
MAppSc, PhD, senior lecturer
Val Gebski, BA, MStat, principal research fellow 
and associate professor
Davina Ghersi, AssocDip, BAppSc, MPH, PhD, 
senior research fellow
Wendy Hague, MB BS, MBA, PhD, senior 
research fellow
Stephane Heritier, MMath, MBA, PhD, senior 
lecturer
Adrienne Kirby, BSc(hons), MSc, senior lecturer
Sally Lord, MB BS, DipPaed, MS, FRACGP, 
research fellow
Martin Stockler, MB BS(hons), MSc, FRACP, 
associate professor
Honorary associates of the CTC
Dr Sally Baron-Hay, ANZGOG
Dr David Bernshaw, ANZGOG
Dr Alison Brand, ANZGOG
Dr Timothy Brighton, ASPIRE
Dr Michael Brown, ALTG
Dr Ian Campbell, SNAC 2
Associate Professor Philip Clarke, Health 
economics
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Dr John Eikelboom, ASPIRE
Dr Michael Friedlander, ANZGOG
Professor Alexander Gallus, PREDICT (ASPIRE)
Professor P Grantley Gill, SNAC
Dr David Goldstein, AGITG
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Dr Trevor Leong, AGITG
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Dr Nicole McCarthy, ANZGOG
Dr Sue-Anne McLachlan, ALTG
Dr Michael Michael, AGITG
Dr Linda Mileshkin, ANZGOG
Dr Christopher Milross, ANZGOG
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Dr Robert Padbury, AGITG 
Dr Timothy J Price, AGITG
Prof Michael Quinn, ANZGOG
Dr Kushwin Rajamani, FIELD
Dr Danny Rischin, ANZGOG
Dr Mark Rosenthal, COGNO
Dr Ben Solomon, ALTG
Dr Christopher Steer, EORTC
Professor William Tarnow-Mordi, BOOST II, INIS
Dr Niall Tebbutt, AGITG
Dr Ru-dee Ting, FIELD
Associate Professor Guy Toner, ANZGCTG
Dr Paul Vasey, ANZGOG
Dr Michelle Vaughan, ANZGOG
Dr Neil Wetzig, SNAC
Professor John Zalcberg, AGITG 
STAFF ACTIVITIES
SUPERVISION OF RESEARCH DEGREES
John Simes
Davina Ghersi: PhD
Peter Grimison: PhD
Kirsten Howard: PhD
Rachel O’Connell: PhD
Michaella Smith: PhD
Anthony Keech
David Burgess: PhD
Gemma Ritchie: PhD
Val Gebski
Goran Hu: PhD
Bee Choo Tai: PhD
Martin Stockler
Haryana Dhillon: PhD
Peter Grimison: PhD
Phillipa Marx: MSc
Michaella Smith: PhD
Yu Yang Soon: MB BS(hons)
DEGR EES COMPLETED 
IN 2006–2007
Karen Bracken: MPH
Davina Ghersi: PhD: ‘Issues in the design: 
conduct and reporting of clinical trials that 
impact on the quality of decision making’
Peter Grimison: MPH
Luke Marinovich: MPH
DEGREES IN PROGRESS
Amy Boland: GradCertHealthInfoMan
Christopher Brown: MBiostat
David Burgess: PhD, ‘Treatment of coronary 
artery disease and its complications’
Xanthi Coskinas: MClinEpi
Kim Gillies: MHlthSc
Peter Grimison: PhD: ‘Integrating quality-of-
life data and traditional outcome measures 
to improve decision making about cancer 
treatments’
Rebecca James: MScMed
Rachel O’Connell: PhD, ‘Risk factor modelling’
Christopher Pardy: MStat
Michaella Smith: PhD, ‘Assessing quality of life 
and arm symptoms following axillary surgery 
for breast cancer’
REPRESENTATION 
ON EXTERNAL COMMITTEES
John Simes
ANZ Breast Cancer Trials Group scientiﬁ c 
advisory committee
Aspirin to Prevent Recurrent Venous Thrombo-
embolism (ASPIRE) trial management 
committee (chair)
Australasian Gastro-Intestinal Trials Group 
(AGITG) scientiﬁ c advisory committee, 
operations executive committee, MAX trial 
management committee, Quasar 2 trial 
management committee, Da Vinci trial 
management committee
Australian New Zealand Clinical Trials Registry 
policy advisory committee
Cancer Institute NSW board
Cholesterol Treatment Trialists Collaboration 
(joint coordinator)
Cochrane Breast Cancer Group co-editor
Cochrane Collaboration prospective meta-
analysis methods working group (coordinator)
Beneﬁ ts of Oxygen Saturation Targeting 
(BOOST II) trial management committee
Current Controlled Trials advisory group
Fenoﬁ brate Intervention and Event Lowering 
in Diabetes (FIELD) management committee, 
executive, audit subcommittee (chair), and 
cost-eﬀ ectiveness subcommittee
Intensive Blood Pressure Reduction for Acute 
Cerebral Haemorrhage Trial (INTERACT) safety 
and data monitoring committee (chair)
International Breast Cancer Intervention Study 
(IBIS-II) international steering committee
International Trials of Aspirin to Prevent 
Recurrent Venous Thrombo-embolism 
(INSPIRE) steering committee (chair)
Long-term Intervention with Pravastatin 
in Ischaemic Disease (LIPID) management 
committee, executive, samples subcommittee 
(chairman)
Mitomycin C, Avastin and Xeloda in Metastatic 
Colorectal Cancer (MAX) trial management 
committee
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NHMRC Clinical Trials Centre management 
review committee and scientiﬁ c advisory 
committee
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Thrombolysis (PCAT) collaborative group 
(co-coordinator)
Sentinel Biopsy versus Axillary Clearance 
(SNAC) trial management committee
Trials editorial board
Virtual Coordinating Centre for International 
Collaborative Cardiovascular Research 
(VIGOUR) statistical group (chair) and a 
VIGOUR leader
World Health Organization clinical trial 
registries technical advisory group
Zoloft Eﬀ ects on Depressive Symptoms 
and Time in Advanced Cancer (ZEST) trial 
management committee
Tony Keech
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and Vascular Disease Prevention executive 
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Intervention (ASPAC) management 
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committee (chairman)
Cholesterol Treatment Trialists’ Collaboration 
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in Diabetes (FIELD) management committee 
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substudies committee, cost-eﬀ ectiveness 
substudies committee
Heart Protection Study (HPS) steering 
committee, executive committee (co-principal 
investigator)
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ISIS Trials Group steering committee
Long-term Intervention with Pravastatin in 
Ischaemic Disease (LIPID) study management 
committee, executive, and quality assurance 
subcommittee
NHMRC Clinical Trials Centre management 
review committee and scientiﬁ c advisory 
committee
National Health and Medical Research Council 
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NSW Department of Health shared assessment 
committee
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Prospective Pravastatin Pooling (PPP) project 
international steering committee
Royal Prince Alfred Hospital clinical trials 
(ethics) subcommittee
University of Sydney College of Health Sciences 
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University of Sydney Faculty of Medicine 
budget advisory committee and faculty awards 
committee, Department of Public Health 
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Virtual Coordinating Centre for International 
Collaborative Cardiovascular Research 
(VIGOUR)
Lisa Askie
Beneﬁ ts of Oxygen Saturation Targeting 
(BOOST) II trial management committee
Cochrane Collaboration handbook advisory 
group
International Clinical Trials Registry Platform, 
World Health Organization, registers working 
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Meta-Analysis of Preterm Patients on Inhaled 
Nitric Oxide (MAPPiNO) Collaboration steering 
group
Neonatal Oxygen Prospective Meta-analysis 
(NeOProM) collaboration steering committee 
(chair)
Perinatal Antiplatelet Review of International 
Studies (PARIS) collaboration steering 
committee, writing committee (chair)
PLoS ONE academic editor
Prevention of Ventilation Induced Lung 
Injury Collaborative Group (Previlig) steering 
committee
Royal Prince Alfred Hospital clinical trials 
(ethics) subcommittee
Xanthi Coskinas
Sentinel Node Biopsy versus Axillary Clearance 
(SNAC) and SNAC 2 trial management 
committees
Peta Forder
Australasian Lung Cancer Trials Group scientiﬁ c 
advisory committee, operational executive 
committee
Cancer Institute NSW Partnership operational 
executive committee
Laparoscopic Approach to Carcinoma of 
the Endometrium (LACE) management 
committee
Corona Gainford
Australasian Gastro-Intestinal Trials Group 
(AGITG)  trials operations committee 
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) trials operations 
committee
Cancer Institute NSW executive committee 
Cancer Institute NSW audit subcommittee
Patrick FitzGerald
Australasian Lung Cancer Trials Group scientiﬁ c 
advisory committee
Australian Pharmaceutical Biostatistics Group 
management committee
Cooperative Trials Group for Neuro-Oncology 
(COGNO) scientiﬁ c advisory committee
Australasian Gastro-Intestinal Trials Group 
scientiﬁ c advisory committee
Val Gebski
Australian New Zealand Breast Cancer Trials 
Group scientiﬁ c committee and ANZ 9311 
management committee
Australasian Gastro-Intestinal Trials Group 
(AGITG) scientiﬁ c advisory committee, MAX  
trial management committee, Da Vinci trial 
management committee
Australasian Kidney Trials Network advisory 
board
Biostatistics Collaboration of Australia steering 
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Joint Radiation Oncology Centre research 
committee
Medical Journal of Australia, statistical 
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NMRC Singapore Indomethacin study for 
closure of PDA safety data and monitoring 
committee
NSW Health Eastern Sydney Area ethics 
committee clinical trials subcommittee
Sentinel Node Biopsy versus Axillary Clearance 
(SNAC) trial management committee
Davina Ghersi
Cochrane Collaboration handbook advisory 
group; methodology review group advisory 
board; prospective meta-analysis methods 
group co-convener; breast cancer group joint 
coordinating editor
World Health Organization International 
Clinical Trials Registry Platform coordinator
Cancer Trials NSW clinical trials committee
NSW Health Pilot Shared Scientiﬁ c Assessment 
Scheme reference group
University of Sydney course advisory 
committee, Master of Health Science and 
Graduate Certiﬁ cate in Health Science (Clinical 
Data Management)
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Australasian Gastro-Intestinal Trials Group 
(AGITG) scientiﬁ c advisory committee, 
operations executive committee, Quasar 2 
trial management committee, Da Vinci trial 
management committee
Peter Grimison
Medical Oncology Group of Australia awards 
committee
Wendy Hague
Aspirin to Prevent Recurrent Venous 
Thromboembolism (ASPIRE) management 
committee
Beneﬁ ts of Oxygen Saturation Targeting 
(BOOST II) management committee
International Neonatal Immunotherapy 
Study (INIS) Australian and New Zealand 
management committee
Long-Term Intervention with Pravastatin 
in Ischaemic Disease (LIPID) management 
committee
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Biostatistics Collaboration of Australia teaching 
committee
Long-Term Intervention with Pravastatin 
in Ischaemic Disease (LIPID) management 
committee
Sally Lord
3rd Annual Meeting of Health Technology 
Assessment International (HTAi) scientiﬁ c 
advisory committee
Danielle Miller
Australasian Gastro-Intestinal Trials Group 
(AGITG) scientiﬁ c advisory committee, 
operations executive committee, biological 
subcommittee 
Australian New Zealand Breast Cancer 
Trials Group
Rebecca Mister
Aspirin to Prevent Recurrent Venous 
Thromboembolism (ASPIRE) management 
committee
Julie Martyn
Australia New Zealand Gynaecological 
Oncology Group research advisory committee, 
study coordinators committee
Gynaecological Cancer Intergroup 
harmonization working group
Sharon Parker
Cochrane Collaboration colloquium policy 
advisory group
Clinical Practice Guidelines For Communicating 
Prognosis and End-of-Life Issues with Adults in 
the Advanced Stages of a Life-Limiting Illness, 
and their Caregivers Australian and New 
Zealand expert advisory group
Rhana Pike
Australasian Medical Writers Association 
executive committee
Ayanthi Salgado 
Australia New Zealand Gynaecological 
Oncology Group study coordinators 
committee, consumer and community 
committee and fundraising committee
Clinical Oncological Society of Australia 
Executive Oﬃ  cers Network clinical trial research 
agreement committee
Kathleen Scott
NSW Cancer Institute partnership operations 
executive committee
Co-operative Trials Group for Neuro-oncology 
(COGNO) operations executive and scientiﬁ c 
advisory committees
Martin Stockler
ACP Journal Club associate editor
Australian New Zealand Breast Cancer Trials 
Group scientiﬁ c advisory committee
Australian New Zealand Germ Cell Trials Group 
scientiﬁ c advisory committee
Australia New Zealand Gynaecological 
Oncology Group scientiﬁ c advisory committee
Australasian Leukaemia and Lymphoma Group 
safety and data monitoring committee
Australasian Lung Cancer Trials Group scientiﬁ c 
advisory committee
Australia Asia-Paciﬁ c Clinical Oncology 
research development workshop steering 
committee
Cancer Council Australia oncology education 
committee
Cancer Council Victoria grant review panel
Cancer Trials NSW trial selection committee 
(chair)
Evidence Based Medicine associate editor
National Breast Cancer Centre hormone 
therapy working group (chair)
National Breast Cancer Centre information 
advisory group (chair)
National Breast Cancer Foundation research 
expert advisory committee
National Cancer Institute quality of life 
intergroup committee
NHMRC oncology grant review panel, palliative 
care research grant review panel, palliative care 
research working group
Burcu Vachan
Australasian Gastro-Intestinal Trials Group 
scientiﬁ c advisory committee, operations 
executive, biological subcommittee, annual 
scientiﬁ c meeting planning committee
Australian and New Zealand Germ Cell Trials 
Group operations executive and executive
Australia New Zealand Gynaecological 
Oncology Group operations executive and 
research advisory committee
Australasian Lung Cancer Trials Group 
operations executive and scientiﬁ c advisory 
committee
Australian New Zealand Breast Cancer Trials 
Group
Cancer Institute NSW infrastructure grant 
subcommittee
Cancer Institute NSW partnership grant 
operational executive committee
Kate Wilson
Australasian Gastro-Intestinal Trials Group 
(AGITG) scientiﬁ c advisory committee, 
operations executive committee, MAX trial 
management committee, Quasar 2 trial 
management committee, Da Vinci trial 
management committee, study coordinators 
subcommittee (chair), annual scientiﬁ c 
meeting planning committee
Academic teaching
John Simes
Decision analysis, 
Master of Public Health and Master of 
Medicine, University of Sydney
Anthony Keech
Controlled clinical trials, Master of Public 
Health and Master of Medicine, 
University of Sydney
University of Sydney Medical Program
Cardiology training, 
Royal Prince Alfred Hospital
Clinical tutor, Royal Prince Alfred Hospital
Lisa Askie
Advanced clinical data management, 
Master of Health Information Management, 
University of Sydney
Advanced systematic reviews, 
Master of Clinical Epidemiology, 
University of Sydney (co-coordinator)
Controlled clinical trials, 
Master of Public Health, 
University of Sydney
Evidence-based medicine in the clinical years, 
University of Sydney Medical Program
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Elizabeth Barnes
Basic sciences in oncology, 
NSW Cancer Council
Principles of statistical inference, 
Biostatistics Collaboration of Australia
Christopher Brown
Controlled clinical trials, Master of Public 
Health and Master of Medicine, 
University of Sydney
Basic sciences in oncology, 
NSW Cancer Council
Peta Forder
Advanced clinical trials, Biostatistics 
Collaboration of Australia
Basic sciences in oncology, 
NSW Cancer Council
Controlled clinical trials, Master of Public 
Health and Master of Medicine, 
University of Sydney
Principles of statistical inference, 
Biostatistics Collaboration of Australia
Corona Gainford
University of Sydney Medical Program
Patrick FitzGerald
Advanced clinical trials, Biostatistics 
Collaboration of Australia
Controlled clinical trials, Master of Public 
Health and Master of Medicine, 
University of Sydney
Principles of statistical inference, 
Biostatistics Collaboration of Australia 
Val Gebski
Advanced clinical trials, Biostatistics 
Collaboration of Australia (coordinator)
Basic sciences in oncology, 
NSW Cancer Council
Controlled clinical trials, Master of Public 
Health and Master of Medicine, 
University of Sydney
Radiation oncology training, RACR trainees, 
Westmead Hospital, NSW Cancer Council
Peter Grimison
University of Sydney Medical Program
Stephane Heritier
Advanced clinical trials, Biostatistics 
Collaboration of Australia
Adrienne Kirby
Basic sciences in oncology, NSW Cancer 
Council
Controlled clinical trials, Master of Public 
Health and Master of Medicine, University of 
Sydney
Principles of statistical inference, Biostatistics 
Collaboration of Australia (coordinator)
Sally Lord
Advanced evaluation of diagnostic tests, 
Master of Public Health and Master of 
Medicine, University of Sydney
Basic sciences in oncology, 
NSW Cancer Council
Controlled clinical trials, Master of Public 
Health and Master of Medicine, 
University of Sydney
Decision analysis, Master of Public Health and 
Master of Medicine, University of Sydney
Evidence-based medicine, 
University of Sydney Medical Program
Luke Marinovich
Evidence-based health care, Master of Applied 
Science (Health Information Management), 
University of Sydney
Rebecca Mister
Advanced clinical data management, 
Master of Health Information Management, 
University of Sydney
Christopher Pardy
Basic sciences in oncology, NSW Cancer 
Council
Principles of statistical inference, 
Biostatistics Collaboration of Australia
Martin Stockler
Australia & Asia-Paciﬁ c Clinical Oncology 
Research Development (ACORD) workshop 
faculty
Clinical epidemiology for physician trainees, 
Royal Prince Alfred Hospital
Critical appraisal of literature for physicians, 
Westmead Hospital
Evidence-based medicine in the clinical years, 
University of Sydney Medical Program 
(chair and coordinator)
Explaining adjuvant therapy, Cancer Institute 
NSW
Making sense of cancer trials, 
Cancer Council NSW
Medical oncology clinical training, 
Royal Prince Alfred Hospital
Oncology and palliative care, 
University of Sydney Medical Program 
(block chair)
Patient-based measures, Master of Medicine, 
University of Sydney (course coordinator)
Quality of life in oncology, 
Cancer Institute NSW
Supportive care research methods, 
Sydney Institute of Palliative Medicine
Burcu Vachan
Basic sciences in oncology, 
NSW Cancer Council
Evidence-based medicine, 
University of Sydney Medical Program
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Journal articles
Ahern V, Boyages J, Gebski V, Moon D, Wilcken 
N. Selective mastectomy in the management 
of locally advanced breast cancer. International 
Journal of Radiation Oncology, Biology, Physics 
2007; 68(4):1010-1017.
Ahern V, Koh ES, Gebski V, Sathiyaseelan Y. 
Paediatric medulloblastoma: patterns of care 
and radiotherapy quality assurance in Australia. 
Australasian Radiology 2007; 51(5): 458–464.
Askie L, Ghersi D, Simes J. Prospective 
registration of clinical trials. Australian Journal of 
Physiotherapy 2006; 52(4): 237–239.
Askie LM, Duley L, Henderson-Smart DJ, Stewart 
LA; on behalf of the PARIS Collaborative Group. 
Antiplatelet agents for prevention of pre-
eclampsia: a meta-analysis of individual patient 
data. Lancet 2007; 369: 1791–1798.
Atlantis E, Barnes EH, Singh MA. Eﬃ  cacy of 
exercise for treating overweight in children and 
adolescents: a systematic review. International 
Journal of Obesity 2006; 30(7): 1027–1040.
Atlantis E, Chow CM, Kirby A, Fiatarone Singh 
MA. Worksite intervention eﬀ ects on physical 
health: a randomized controlled trial. Health 
Promotion International 2006; 21(3): 191–200.
Atlantis E, Chow CM, Kirby A, Fiatarone Singh 
MA. Worksite intervention eﬀ ects on sleep 
quality: a randomized controlled trial. Journal of 
Occupational Health Psychology 2006; 11(4): 
291–304.
Baigent C, Keech A, Kearney P, Collins R, Simes J; 
on behalf of the Cholesterol Treatment Trialists’ 
Collaboration. Eﬃ  cacy and safety of cholesterol-
lowering treatment—authors’ reply [letter]. 
Lancet 2006; 367(9509): 470–471.
Beslija S, Bonneterre J, Burstein H, Cocquyt V, 
Gnant M, Goodwin P, Heinemann V, Jassem 
J, Kostler WJ, Krainer M, Menard S, Petit T, 
Petruzelka L, Possinger K, Schmid P, Stadtmauer 
E, Stockler M, Van Belle S, Vogel C, Wilcken N, 
Wiltschke C, Zielinski CC, Zwierzina H. Second 
consensus on medical treatment of metastatic 
breast cancer. Annals of Oncology 2007; 18(2): 
215–225.
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Wiltschke C, Zielinski CC, Zwierzina H. Second 
consensus on medical treatment of metastatic 
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215–225.
Brand AH, Bull CA, Cakir B. Vaginal stenosis in 
patients treated with radiotherapy for carcinoma 
of the cervix. International Journal of Gynecological 
Cancer 2006; 16: 288–293.
Burgess DC, Burgess MA, Leask J. The MMR 
vaccination and autism controversy in the United 
Kingdom 1997–2005: inevitable community 
outrage or a failure of risk communication? 
Vaccine 2006; 24: 3921–3928.
Burgess DC, Kilborn MJ, Keech AC. Interventions 
for prevention of postoperative atrial ﬁ brillation 
and its complications after cardiac surgery: a 
meta-analysis. European Heart Journal. 2006; 27: 
2846–2857.
Bushnell CD, Griﬃ  n J, Newby LK, Goldstein LB, 
Mahaﬀ ey KW, Graﬀ agnino CA, Harrington RA, 
White HD, Simes RJ, Caliﬀ  RM, Topol EJ, Easton 
JD. Statin use and sex-speciﬁ c stroke outcomes 
in patients with vascular disease. Stroke 2006; 
37(6): 1427–1431.
Butow PN, Solomon M, Young JM, Whelan 
T, Salkeld G, Wilson K, Harrison JD, Hruby G, 
Mansour O, Kennedy N, Tattersall MH. Consumer 
impact of an interactive decision aid for rectal 
cancer patients oﬀ ered adjuvant therapy. 
Colorectal Disease 2006; 8(8): 676–682.
Byth K, Cox DR, Forder P. Assessing the 
relationship between symptoms of allergic 
rhinoconjunctivitis and pollen counts. Australian 
and New Zealand Journal of Statistics 2006; 48(4): 
417–428.
Cebon J, Hargreaves C, Stockler M, Nowak A, 
Dhillon H, Dickman B, Gebski V; Australasian 
Gastro-Intestinal Trials Group (AGITG) AG0001H 
Investigators. Somatostatin receptor expression, 
tumour response, and quality of life in patients 
with advanced hepatocellular carcinoma treated 
with long-acting octreotide. British Journal of 
Cancer 2006; 95(7): 853–861.
Chan QW, Upshur R, Singh JA, Ghersi D, Chapuis 
F, Altman D. Waiving conﬁ dentiality for the 
greater good. BMJ 2006; 332: 1086–1089.
Charles K, Rivory LP, Stockler MR, Beale P, Beith 
J, Boyer M, Clarke S. Predicting the toxicity of 
weekly docetaxel in advanced cancer. Clinical 
Pharmacokinetics 2006; 45(6): 611–622.
Clemons M, Cole DE, Gainford MC. can bone 
markers guide more eﬀ ective treatment of bone 
metastases from breast cancer? Breast Cancer 
Research and Treatment 2006; 97: 81–90.
Clemons M, Dranitsaris G, Cole DEC, Gainford 
MC. too much, too little, too late to start again? 
assessing the eﬃ  cacy of bisphosphonate in 
patients with bone metastases from breast 
cancer. Oncologist 2006; 11: 227–233.
Collins P, Flather M, Lees B, Mister R, Proudler AJ, 
Stevenson JC; on behalf of the WHISP (Women’s 
Hormone Intervention Secondary Prevention 
Study) Pilot Study Investigators. Randomized 
trial of eﬀ ects of continuous combined HRT on 
markers of lipids and coagulation in women with 
acute coronary syndromes: WHISP Pilot Study. 
European Heart Journal 2006; 27(17): 2046–2053.
Copt S, Heritier S. Robust alternatives to the 
F-test in mixed linear models based on MM-
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